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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) is closely associated with obesity and 
insulin resistance. To better understand the pathophysiology of obesity-associated 
NAFLD, the present study examined the involvement of liver and adipose tissues in 
metformin actions on reducing hepatic steatosis and inflammation during obesity. Also, 
the importance of AMPK in regulating the anti-steatosis and anti-inflammatory 
properties of metformin was examined. 
C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity-
associated NAFLD and treated with metformin (150 mg/kg/d) orally for the last four 
weeks of HFD feeding. Compared with HFD-fed control mice, metformin-treated mice 
showed improvement in both glucose tolerance and insulin sensitivity but also a 
decrease in hepatic steatosis and liver inflammation associated with an increase in the 
phosphorylation of liver AMP-activated protein kinase (AMPK). However, metformin 
treatment did not significantly alter adipose tissue AMPK phosphorylation and 
inflammatory responses. In vitro studies showed that metformin directly decreased 
steatosis in hepatocytes and inflammation in both hepatocytes and macrophages, and is 
AMPK associated. Further in vitro studies confirmed the importance of AMPK in 
regulating the anti-steatosis and anti-inflammatory effects of metformin in hepatocytes 
and macrophages. 
Taken together, these results suggest that metformin protects against obesity-
associated NAFLD largely through direct effects on decreasing hepatocyte fat deposition 
and on inhibiting inflammatory responses in both hepatocytes and macrophages. 
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NOMENCLATURE 
AMPK 5’ Adenosine Monophosphate-activated Protein Kinase 
ACC Acetyl-CoA Carboxylase 
AP-1 Activator Protein 1 
BMDM Bone Marrow-Derived Macrophage 
ChREBP Carbohydrate Response Element-Binding Protein 
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IL-6 Interleukin-6 
IR Insulin Resistance 
v 
ITT Insulin Tolerance Test 
JNK c-Jun N-terminal Kinase 
LXR Liver X Receptor 
LPS Lipopolysacharride 
MCD Methionine- and Choline-Deficient 
MCP-1 Monocyte Chemotactic Protein-1 
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NAFLD Nonalcoholic Fatty Liver Disease 
NASH Nonalcoholic Steatohepatitis 
NFκB Nuclear Factor kB 
PAMPS Pathogen-Associated Molecular Patterns 
PGC1-α PPAR Gamma Co-activator 1-α 
ROS Reactive Oxygen Species 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
RXR Retinoid X Receptor 
SREBP-1c Sterol Regulatory Element-Binding Protein 1c 
SVC Stromal Vascular Cell 
T2DM Type 2 Diabetes Mellitus 
TG Triglycerides 
TLR-4 Toll-Like Receptor-4 
TNF-α Tumor Necrosis Factor-α 
VLDL Very Low Density Lipoprotein 
vi 
WAT White Adipose Tissue 
WT Wild-Type 
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CHAPTER I 
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases that is 
increasingly shown to be associated with elevated risk of complications and liver-
specific mortality (1). At present, there has yet to be a standard treatment for managing 
NAFLD. Since the occurrence of NAFLD is highly prevalent in obese and type 2 
diabetic individuals (2,3), suggested approaches in managing patients with NAFLD and 
concurrent diabetes aim at improving glucose metabolism, which include metformin 
treatment.  
Metformin, a drug that is widely used in controlling type 2 diabetes mellitus 
(T2DM), has been increasingly shown to be beneficial in improving NAFLD. The 
mechanism of metformin is mainly considered to be closely associated with AMP-
activated protein kinase (AMPK), an energy-sensing molecule that regulates cellular and 
systemic energy homeostasis. Metformin not only is able to decrease hepatic 
gluconeogenesis, but also, in many studies, has been shown to decrease hepatic steatosis 
(4,5). But, whether or not metformin decreases hepatic inflammatory damage, 
histological features of NASH remain controversial. Although there are studies 
supporting the effect of metformin in decreasing hepatic inflammation (6,7), the exact 
cellular mechanisms as to how metformin decreases liver inflammation remains unclear. 
Knowing that liver inflammation is important in the progression of NAFLD, we would 
like to focus on exploring the cellular mechanisms of how metformin decreases liver 
inflammation. Therefore, the main hypothesis of this dissertation is that metformin could 
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ameliorate hepatic steatosis and liver inflammation through AMPK activation, directly 
affecting hepatocytes and macrophages, and indirectly improving adipose tissue 
phenotype in an obesity-related NAFLD mice model.  
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CHAPTER II 
LITERATURE REVIEW*  
NON-ALCOHOLIC FATTY LIVER DISEASE, OBESITY, AND TYPE 2 
DIABETES 
Non-alcoholic fatty liver disease (NAFLD) is a clinical condition that 
encompasses the whole spectrum of liver diseases including hepatic steatosis, non-
alcoholic steatohepatitis (NASH), and cirrhosis without significant alcohol consumption. 
While simple lipid accumulation in the liver is generally considered as histologically 
benign, it could progress to NASH during overt liver necroinflammation. Moreover, the 
risk of liver progression from benign to NASH increases is set as lipid accumulation of 
more than 5% the liver volume or weight, or hepatocytes containing more than 5% 
visible intracellular triglycerides, by means of either imaging or biopsy (8). Chronic 
progression of NASH could potentially progress to cirrhosis, liver failure and liver 
cancer. Therefore, NASH is considered as the more progressive and damaging form of 
NAFLD. It has been estimated that the prevalence of NAFLD ranges from 6% to 35% 
with a median of 20% worldwide in the general population (2,9). Among the biopsied 
NAFLD patients, it is estimated that the prevalence of NASH is approximately  
___________ 
* Part of this chapter is reprinted with permission from Hepatic de Novo Lipogenesis 
and Regulation of Metabolism, Hepatic Lipogenesis: Nutritional Control and 
Pathophysiological Relevance, 2015, 211-234, Woo, S.-L., Guo, T., and Wu, C. (original 
copyright notice as given in the publication in which the material was originally 
published) With permission of Springer. 
 
  
4 
 
30% (10). In addition, NAFLD is the most common liver disease in industrialized 
Western countries. In fact, NASH is becoming a more common cause for liver 
transplantation in the United States, and is on the path of becoming the most common 
(11,12). 
 NAFLD is increasingly observed to coexist with obesity and insulin resistance, 
which are components of metabolic syndrome that increases the risk of cardiovascular 
disease (13). The close relationship between obesity, insulin resistance, and NAFLD 
came from the observations in fatty changes in liver of obese patients, and in the 
presence of hyperinsulinemia and glucose intolerance in obese patients (14-16). In fact, 
recent studies estimated that the prevalence of NAFLD among obese patients is 60% 
(10), and that the prevalence of NAFLD among diabetes patients is 50% (17).  
 Although the pathogenesis of NAFLD is not fully understood, NAFLD could be 
represented by a “two hits” model that was first proposed by Day and James (18). The 
first “hit” requires the production of hepatic steatosis. Factors that contribute to hepatic 
steatosis include increased hepatic de novo lipogenesis, decreased hepatic β-oxidation, 
increased free fatty acid supply from adipose, and decreased very-low density 
lipoprotein (VLDL) triglyceride output (19-21). The second “hit” requires a source of 
oxidative stress capable of initiating significant lipid peroxidation, leading to histological 
damage (18); though nowadays, there is more and more evidence showing that the 
second “hit” could be promoted by a chronic proinflammatory environment induced by 
obesity-related adipose tissue dysfunction and obesity-induced insulin resistance. This is 
important, as adipose dysfunction is a critical source of adipocytokines such as 
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interleukin-6 (IL-6) and tumor necrosis factor- α (TNF-α) that could promote liver 
inflammation (NASH) (22). However, the sequence of these “two hits” has been 
challenged in the sense that inflammation could precede hepatic steatosis and the 
metabolic events present in NAFLD are suggested to occur in a parallel rather than a 
consecutive manner. In addition, emerging evidence suggests that there are multiple 
factors contributing to NAFLD concurrently. These factors that lead to liver 
inflammation include gut-derived mediators, adipose-derived mediators, and 
endoplasmic reticulum stress. Therefore, a “multiple parallel hits” concept might be a 
more precise reflection of the current conception of NAFLD pathology (19).  
Studies in rodents and humans have revealed that the excessive accumulation of 
triglyceride in the liver is mainly caused by an overflow of fatty acids from 
hypertrophied and insulin resistant adipose tissue, and from increased de novo 
lipogenesis (DNL) in the liver; but is less contributed by fatty acid disposal through β-
oxidation or VLDL export (23). In fact, isotopic quantitative analysis in NAFLD patients 
showed that labelled triglyceride in the liver was distributed around 59% derived mainly 
from adipose lipolysis, 26% derived from DNL, and 15% derived from the diet (24). 
Importantly, the lipogenic rate, which is normally inhibited during fasted state, was 
already elevated during.  
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NUTRITION REGULATION OF LIPOGENESIS 
  Since the liver is the major site of de novo lipogenesis (DNL) in humans (25), 
it is worth mentioning the effects of nutrients and how they affect hepatic lipogenesis 
when in excess. Hepatic DNL is generally most activated by high-carbohydrate feeding 
but inhibited by high-fat feeding and fasting. Overfeeding of carbohydrate enhances the 
conversion of carbohydrate into fatty acids. Perhaps one very good example of this 
phenomenon is the clinical observation of fatty infiltration in liver induced by high 
dextrose content of total parenteral nutrition (26).  
Numerous studies have also shown the lipogenic effect of carbohydrate overfeeding 
(27,28). Particularly, during massive overfeeding of a carbohydrate-rich diet in the Guru 
Walla model – a Cameroon ritual where teenage boys deliberately overconsume a 7000 
kcal/day, high carbohydrate diet (70%) but just a total of 4 kg fat consumption in over 10 
weeks, which they gain 12 kg of fat (29).  However, during less extreme carbohydrate 
feeding, DNL is less significant. As shown by Acheson et al., DNL becomes significant 
after maximum whole-body glycogen storage of approximately 700-1000 g is reached, 
which equates to averagely 800 g/day of carbohydrate for 4 days as shown in his study. 
In other words, the excess carbohydrate during short-term ingestion of a large amount of 
carbohydrate should go towards saturation of glycogen storage before DNL becomes 
significant – net lipid synthesis exceeds glycogen storage, and  carbohydrate and lipid 
oxidation (30,31).  
While the above given examples did not explain the lipogenic effect related to 
the composition of carbohydrate, it is generally recognized that glucose is the main 
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lipogenic substrate in monogastric animals. Fructose is also now emerging as a strong 
lipogenic stimulator. Although fat is generally thought to antagonize lipogenesis, there is 
accumulating evidence that different fatty acids will have different effects on 
lipogenesis. And, these will be discussed further in the sections below.   
 
Glucose  
The role for glucose in stimulating DNL has long been recognized. This is 
because glucose, through its metabolism, provides substrates that are needed for DNL. 
Furthermore, as a signaling molecule, glucose has a stimulatory effect on the expression 
of several key lipogenic enzymes, in particular acetyl-CoA carboxylase (ACC) (32,33). 
However, this role should be interpreted as a role for glucose metabolism, but not 
glucose, per se, in stimulating DNL. Physiologically, glucose metabolism is tightly 
coupled to insulin. Thus, it is very difficult to separate the effect of glucose from that of 
insulin on DNL. Since the identification and functional characterization of carbohydrate 
response element-binding protein (ChREBP) in controlling the expression of lipogenic 
enzymes (34), it became largely accepted that ChREBP and sterol regulatory element-
binding protein-1c (SREBP-1c) mediate the effect of glucose and insulin, respectively, 
on stimulating lipogenic enzyme expression.  
 The stimulatory effect of glucose, strictly speaking glucose metabolism, on DNL 
is manifested by the finding that glucokinase overexpression in rodents led to hepatic 
steatosis (35,36). A simple explanation is that enhancing glycolysis provides substrates 
for DNL. Because generation of fructose-1,6-bisphosphate from fructose-6-phosphate is 
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a rate-determining step of glycolysis, overexpression of a kinase-dominant 6-
phosphofructo-2-kinase was used to enhance glycolysis (36). Of interest, DNL was not 
increased; although glycolysis was enhanced. Further mechanistic investigation 
demonstrated the importance of pentose phosphate shunt in activating ChREBP, and, 
likely, in generating NADPH, another required substrate of DNL, to enable DNL (36). In 
that study, insulin levels were decreased in response to glucokinase overexpression. 
This, however, does not imply a stimulatory effect of glucose (metabolism) on DNL that 
is independent of insulin. Indeed, enhancing glycolysis through overexpression of 
glucokinase generates effects on glycolysis that are almost identical to the combined 
effect of glucose and insulin.   
 
Fructose 
 Fructose has received much attention recently due to its association with 
extensive dietary consumption in the modern society, and its close relationship with 
metabolic diseases such as NAFLD, insulin resistance, and dyslipidemia, due mostly to 
the lipogenic capacity of fructose.  
 Fructose is a monosaccharide (as are glucose and galactose) that occur in the 
form of sucrose, a disaccharide composed of fructose and glucose, or in the form 
fructose alone. After absorption, fructose is rapidly phosphorylated by fructokinase into 
fructose-1-phosphate in hepatocytes. Fructose-1-phosphate is then converted to 
glyceraldehyde and dihydroxyacetone, which could feed into the regular glycolytic 
pathway. This is of importance because the fructose metabolic pathway is able to bypass 
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the main regulatory step of glycolysis, which is 6PFK1. In addition, fructose uptake is 
not regulated by insulin nor does fructose stimulate insulin secretion as much as glucose 
does, and fructokinase has almost 10 times higher enzyme activity than glucokinase 
(37). Moreover, Havel et al. showed that an equivalent dose of glucose and fructose (1 
g/kg dose) produced dissimilarities in their levels reflected in blood. Blood fructose level 
increases minimally to approximately 0.5mM, which is relatively low when compared to 
10mM postprandial blood glucose level (38). This suggests that fructose is highly 
metabolized upon the first pass to the liver.  
There is no doubt that fructose stimulates the mRNA expression of lipogenic 
enzymes such as ACC and FAS (39). However, this does not mean that all the fructose is 
metabolized in favor of lipogenesis. In fact, in a single-blinded, randomized, crossover 
study, it was found that 35% of the fructose was oxidized, approximately 38% appeared 
to form glycerol in the form of VLDL-triacylglycerol, 0.4% appeared as de novo fatty 
acids in the form of VLDL-triglyceride, and some likely remained storage as liver 
glycogen after a fructose load of 0.75 g/kg (40).  
 The contemporary issue is that the over-consumption of sucrose and high-
fructose corn syrup in our daily food products likely is amplifying the significance of the 
lipogenic effect of fructose (41). Moreover, fructose could induce hepatic and 
extrahepatic insulin resistance as shown by Dirlewanger et al. (42). Also, high fructose 
consumption has been highly correlated with visceral obesity (43,44). This is important 
as insulin resistance and obesity are highly related to metabolic diseases such as NAFLD 
and dyslipidemia (45-47), which will be discussed further.    
10 
 
Fatty acid composition  
 The earliest report of the inhibitory effect of dietary lipid on hepatic lipogenesis 
is in 1950 when Masoro et al. showed that there were less labelled [14C] fatty acids 
generated from [14C] glucose in rat livers after 3 days of a diet containing 60% butter, 
compared to rats that were fed a 60% glucose diet (48). Due to the heterogeneity of 
dietary lipid composition, such as saturated, mono-, and poly-unsaturated fatty acids, 
numerous subsequent studies then aim to clarify if all dietary fats have equal effects on 
diminishing DNL. Saturated fatty acids promotes fatty acid synthesis (49), whereas 
polyunsaturated fatty acids (PUFA), both n-3 and n-6 PUFAs, are able to suppress the 
hepatic lipogenic enzymes (50-53).  Interestingly, palmitoleate, a monounsaturated fatty 
acid, seems to controversially stimulate DNL as observed in the inducing effect of 
palmitoleate in increasing FAS mRNA expression in mice liver, as well as an increase in 
hepatic lipid accumulation (54).  
 
Palmitoleate  
 As mentioned above, palmitoleate controversially increases DNL. In two lines of 
mice studies (55,56), palmitoleate was thought to decrease hepatic lipid accumulation 
due to inhibition of FAS expression in liver. In contrast, Petit et al. reported that 
circulating palmitoleate level might positively correlate with the degree of hepatic 
steatosis in human subjects (57). A recent mechanism study by Guo et al. reported 
similar effects of palmitoleate on inducing hepatic DNL and hepatic steatosis in mice 
(54). This is supported by an increase in expression of SREBP-1c and FAS upon 
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palmitoleate treatment in hepatocytes cell line. Interestingly, palmitoleate 
supplementation in mice also improved insulin sensitivity and glucose tolerance, thus 
dissociating the association between insulin resistance and hepatic steatosis. In 
particular, these effects are found to be activated via liver Akt signaling by palmitoleate 
(54), which is important as SREBP-1c is known to be activated via the Akt-mTORC1 
pathway and gluconeogenesis is known to be downregulated via Akt-FOXO1 pathway. 
Also, the ability of palmitoleate to reduce liver and macrophage inflammatory response 
in this study might also help explain the improvement in insulin resistance (54).  
 The findings of this study provide a new insight of how different lipid 
composition could have profound effects on human physiology; as palmitoleic acid is a 
monounsaturated fatty acid that could be a dietary component and more importantly, 
could also be endogenously produced by adipocytes. The latter effect has important 
implication for further investigation on elucidating the cross-talk between adipose tissue 
and liver in the pathophysiology of metabolic diseases such as insulin resistance and 
NAFLD. 
  
OBESE ADIPOSE TISSUE AND NAFLD 
 Adipose tissue not only functions as a mere energy/fat storage but is also a highly 
active endocrine organ that is made up of different cell populations including adipocytes, 
macrophages, and other immune cells. In an obese state, adipose tissue dysfunction can 
develop, resulting in lipid “overspill” and a chronic state of pro-inflammatory response, 
both of which could eventually lead to NAFLFD.  
12 
 
Obesity and liver fat accumulation 
Under normal conditions, circulating free fatty acids (FFAs) are contributed by 
adipose tissue lipolysis during post-absorptive conditions. These FFAs could enter the 
liver to be repackaged for fatty acid transport as VLDL. The major source of FFAs that 
enter the liver could come from subcutaneous adipose tissue, after passing through the 
splanchnic tissue and entering the hepatic artery and portal vein.  
However, under obese condition, the proportion of FFAs coming from visceral 
adipose tissue entering the liver increases. It is of no surprise because visceral adipose 
tissue is known to be more pronounced, than other adipose tissues, to be drained by the 
portal circulation, which connects to the liver (58). Clearly, the major source of FFAs 
that enter the liver would come from increased visceral adipose lipolysis during post-
absorptive and obese conditions (59). Indeed, as shown by a study that examined the 
relative FFAs in the portal vein originating from visceral adipose tissue of lean and 
obese subjects, it was found that while the hepatic FFA delivery from visceral adipose in 
lean subjects accounts for 5-10%, the proportion of hepatic FFA delivery from visceral 
adipose in obese subjects could be as high as 30% or more (60). This is important 
because visceral adipose tissue has been highly implicated to have a positive association 
with metabolic diseases, including NAFLD and insulin resistance.  
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Obesity-associated inflammation 
During obese condition, the adipose tissue is undergoing many alterations 
including, adipocyte hypertrophy, nutrient overflow, increased antigens exposure from 
the gut, organelle stresses, all of which could directly or indirectly trigger the immune 
response in adipose tissue (61). In fact, adipose tissue inflammation, which is most 
represented by macrophage infiltration and increased inflammatory markers is positively 
associated with increased body fat mass/visceral fat, and adipocyte hypertrophy, and is a 
reversible process after weight loss (62,63). Similarly, adipose tissue macrophage 
infiltration is also greater in the adipose tissue of subjects with NAFLD (64).  
In adipose tissue reside different cell populations including adipocytes and 
macrophages. In a condition of nutrient excess, as seen in obesity, these 
nutrients/metabolic signals could trigger pro-inflammatory intracellular pathways in 
adipocytes. The activation of the pro-inflammatory pathways, such as the c-Jun N-
terminal kinases (JNK) and IκB kinase (IKK) pathways could then induce a low-level 
production of cytokines such as tumor necrosis factor- α (TNF-α), interleukin-1β (IL-
1β), interleukin-6 (IL-6), monocyte chemoprotectant-1 (MCP-1) (65). Chronic activation 
of these inflammatory pathways and production of these cytokines may promote the 
recruitment and activation of immune cells, including macrophages, mast cells, T cells, 
etc. that in turn increases the production of those pro-inflammatory cytokines, driving 
the adipose tissue towards a state of low-grade inflammation. In effects, chronic state of 
low-grade inflammation induced by those cytokines could not only disrupt insulin 
signaling, resulting in insulin resistance, but also interrupt systemic metabolism. For 
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example, the discovery that TNF-α level was highly elevated in obese mice and that it 
could impair insulin signaling and glucose uptake in adipocytes have led to work in 
identifying the role of TNF-α in disrupting the insulin receptor signaling (66,67). Indeed, 
insulin resistance is important in linking obesity with metabolic diseases such as non-
insulin dependent diabetes mellitus, NAFLD, and cardiovascular diseases. 
In an obese adipose tissue, not only low-grade inflammation induces insulin 
resistance locally (i.e. adipose tissue), but the pro-inflammatory cytokines could also 
lead to insulin resistance in the peripheral tissues such as the liver (61).  
 
HEPATIC INSULIN RESISTANCE AND NAFLD 
 Insulin resistance refers to insulin-responsive cells (such as hepatocytes, 
adipocytes, and myocytes) failed to respond to insulin signaling and the signal 
transduction is disrupted, therefore insulin-stimulated metabolism is impaired. 
The liver represents an important metabolic organ that majorly participates in the 
metabolism of glucose and lipid – including gluconeogenesis and lipogenesis. The 
control of such metabolic pathways lies mainly in the ability of hepatocytes to response 
properly to the signaling of insulin. Appropriate insulin signaling in the liver suppresses 
gluconeogenesis and promotes lipogenesis. However, during a state of hepatic insulin 
resistance, insulin signaling fails to suppress gluconeogenesis but insulin-induced 
lipogenesis remains functional. This “selective insulin resistance” paradox was proposed 
by Brown and Goldstein (68), and that impairment of insulin signaling diverges after 
protein kinase B (also known as Akt), suggesting that insulin-mediated suppression of 
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forkhead box protein O1 (FOXO1) is impaired while insulin-mediated sterol regulatory 
element-binding protein-1c (SREBP-1c) remains sensitive (69). Moreover, 
hyperinsulinemia that usually accompanies insulin resistance, as a compensation 
mechanism of the pancreas due to hyperglycemia, could further amplifies the insulin-
mediated lipogenesis. What causes the impaired suppression of gluconeogenesis but 
intact lipogenesis remains poorly understood. Accordingly, many theories have arisen to 
explain the pathology of this insulin signaling paradox (70-72). Of the very recent, there 
is evidence suggesting that over-nutrition-induced overproduction of triglyceride 
metabolites could result in hyper-activation of atypical protein kinase C (aPKC), and that 
this might be the key in selectively impairing FOXO1 phosphorylation while stimulation 
of SREBP-1c remain elevated (72). However, to be on the conservative side, more 
studies are still required to fully elucidate the molecular mechanisms of this selective 
insulin resistance.  
It is important to recognize that there hasn’t been a cause-and-effect relationship 
established between NAFLD and hepatic insulin resistance. This could be evidenced by 
the work of Samuel et al. (73). The authors showed that knocking down the expression 
of protein kinase Cε (PKCε), which is known to impair insulin signaling, was able to 
reverse insulin resistance despite hepatic steatosis. They further showed that liver 
accumulation of diacylglycerol, which is a lipid metabolite, could activate PKCε, and 
that PKCε could directly bind and inhibit the activity of insulin receptor tyrosine kinase, 
thus impairing insulin signaling (73). In addition, hepatic steatosis is not always 
associated with insulin resistance, as evidenced by the work of Monetti et al., showing 
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that the hepatic steatosis induced by overexpression of diacylglycerol acyltransferase 2 
(DGAT2), the committed step in triglyceride synthesis, did not result in insulin 
resistance (74). So, this begs the question: what accounts for the discrepancies of the 
existence between hepatic steatosis and insulin resistance? It has been suggested that 
when steatosis is associated with an accumulation of a specific lipid component, fatty 
acid, or lipid derivative, these component(s) could improve or impair insulin sensitivity 
(74). Indeed, a recent animal study by Huo et al. found an association between hepatic 
steatosis and an increase in palmitoleate level of the lipid content in the steatotic liver 
(75). To further verify the significance of this finding, Guo et al. demonstrated that 
palmitoleate was able to induce hepatic steatosis, by stimulating lipogenesis, but 
improve insulin sensitivity at both the hepatic and systemic level. More interestingly is 
that palmitoleate was able to suppress liver inflammation. This indicates that the 
improvement of insulin sensitivity by palmitoleate is, at least partly, due to the 
suppression of liver inflammation (54). This important finding also signifies that 
NAFLD is affected by nutrients themselves.  
 
MACROPHAGE INVOLVEMENT IN NAFLD 
 The liver is a complex tissue composed of various cell population. Hepatocytes, 
which represents 60-80% of all liver cells, are responsible for most of the important 
metabolic and xenobiotic pathways of the liver. In the liver also resides various cells, 
including Kupffer cells (KCs) (i.e. the residing macrophages), hepatic stellate cells, 
sinusoidal endothelial cells, and natural killer (NK) cells that could contribute greatly to 
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the initiation of liver inflammation, with the consequence of recruiting other immune 
cells such as dendritic cells, monocytes, macrophages, etc. During both acute and 
chronic liver inflammation, these immune cells are activated by damage-associated 
molecular patterns (DAMPS), which are endogenous molecules released from damaged 
cells, and pathogen-associated molecular patterns (PAMPS), which are exogenous 
molecules derived from microbes (76). Together, PAMPS and DAMPS could act as 
ligands for receptors such as toll-like receptors (TLRs), and NOD-like receptors (NLRs), 
leading to the activation of the pro-inflammatory pathways, often times including 
transcription factors such as nuclear factor-kappa B (NF-B), stress kinase such as c-Jun 
N-terminal kinases (JNKs). This then leads to increased production of pro-inflammatory 
cytokines such as TNF-α, IL-1β, IL-6, IL-18, etc. that not only perpetuates the 
recruitment of immune cells, but also act as signaling molecule to exacerbate the already 
damaged parenchyma and/or further hepatocyte apoptosis. If the inflammation remains 
unresolved, the chronic activation of the pro-inflammatory pathways could trigger 
fibrotic response as the generation of myofibroblasts replace dead hepatocytes. This 
irreversible damage signifies the onset of declining hepatic functions. 
Kupffer cells are liver-specific macrophages that reside in the liver sinusoids and 
constitute approximately 20% of the liver non-parenchymal cells (77). This is because 
Kupffer cells rapidly recognize exogenous and endogenous immunoreactive materials 
including LPS, FFAs, etc., and are able to initiate interactions by releasing various 
mediators including chemokines, cytokines, ROS, nitric oxide, etc. (78). In effect, these 
inflammatory mediators could recruit other immune cells such as natural killer (NK) 
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cells, NK T-lymphocytes, and even additional blood-derived macrophages. Much 
evidence suggests that activation of Kupffer cells are critical in the pathogenesis of 
NAFLD (79-81). As shown by experimental and human models of NAFLD, during the 
pathogenesis of NAFLD, an obese phenotype, due to numerous dietary factors (such as 
high-fat and high-fructose diets), could highly contribute to increased bacterial 
translocation, thus increased LPS exposure, because of altered intestinal bacteria 
population, and increased epithelial permeability (82-84). This increases the chance of 
activation of Kupffer cell by LPS-induced signaling of TLR-4. For example, TLR-4 
mutant mice are defective in LPS signaling (85), and TLR-4-deficient mice are found to 
be protective against liver steatosis, inflammation, and fibrosis as shown by liver 
histology (86). It is also worth noting that FFAs are known ligands for TLR-4 (87), 
indicating that activation of Kupffer cells does not solely induced by LPS, but also by a 
FFAs-enriched environment, as in the case during obese and/or NAFLD conditions. 
AMPK: A PLEIOTROPIC KINASE THAT REGULATES METABOLISM AND 
INFLAMMATION 
AMPK is a heterotrimeric protein complex that comprises the catalytic α-subunit, 
and the regulatory β- and γ-subunits. AMPK is usually described as an energy on/off 
switch that responds in a very sensitive manner to the cellular energy status, which is the 
ATP status. Specifically, AMPK highly responds to the cellular ADP/ATP and 
AMP/ATP ratio, both of which signifies energy stress or low energy status of the cell. 
During times of energy stress, the increase in AMP concentration could act as an 
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allosteric activator by binding to the γ-subunit of AMPK, thus making it more 
susceptible for phosphorylation of AMPK at site Thr 172 by its upstream kinase, liver 
kinase B1 (LKB1); also inhibiting dephosphorylation by protein phosphatases (88). In 
the absence of changes in AMP concentration, AMPK can also be alternatively 
phosphorylated by the Ca2+/ calmodulin-dependent kinase kinases (CaMKKs), especially 
CaMKKβ, in response to a change in intracellular Ca2+ changes (89).  
 As a pleiotropic kinase, upon activation of AMPK, it signals the downstream via 
phosphorylation of the substrates, both metabolic enzymes and regulatory proteins, 
thereby acutely activating or inhibiting a metabolic pathway. For example, AMPK plays 
important role in regulating glucose metabolism by direct phosphorylation of TBD1C1 
(Tre2/Bub2/Cdc16 domain protein1), thereby promoting GLUT4 trafficking to the 
plasma membrane, increasing glucose uptake in skeletal muscle (90). AMPK also plays 
a role in regulating lipid metabolism. Particularly, AMPK phosphorylates ACC and 3-
hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, thereby inactivating fatty acid 
synthesis and cholesterol synthesis respectively (91,92). Since inhibition of ACC would 
decrease the generation of malonyl-CoA, which could inhibit carnitine palmitoyl 
transferase 1 (CPT1), this effect by AMPK could release the inhibition of CPT1, thereby 
promoting fatty acid oxidation (93). Other than glucose and lipid metabolism, AMPK is 
also involved in enhancing mitochondrial biogenesis via phosphorylation of peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) (94), and inhibiting 
protein synthesis via inhibiting the mechanistic target-of-rapamycin complex-1 
(mTORC1) (95). 
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 Due to the effect in regulating metabolism, AMPK has been increasingly shown 
to have an anti-inflammatory effect on immune cells. Normally, immune cells such as 
macrophages, neutrophils, dendritic cells and T cells mainly rely on oxidative 
metabolism to generate ATP in their inactivated state. However, in an activated state, 
these immune cells would switch to rely mainly on aerobic glycolysis. For example, 
TLR agonist-activated dendritic cells showed a switch to aerobic glycolysis, and this is 
associated with reduced AMPK activation, and is inhibited by pharmacological AMPK 
activation (96). Further studies on macrophages indicated that downregulation of AMPK 
is associated with a decrease in pro-inflammatory cytokine production, such as TNF-α 
and IL-6, and a switch to a M2 anti-inflammatory phenotype (97). Further mechanistic 
studies by examining AMPK-β1 deficient macrophages showed that the resulted 
increase in ACC activity and decrease in fatty acid oxidation caused an increase in the 
accumulation of pro-inflammatory diacylglycerol, thereby a skewing of the macrophages 
to a M1 pro-inflammatory phenotype in vivo (98).  
 
METFORMIN ACTION IN THE LIVER  
 Metformin belongs to the biguanide family of anti-diabetic drug. It is originally 
derived from galegine present in French lilac, which was used to treat many illnesses for 
centuries. The effectiveness of metformin in lowering blood glucose has been recorded 
since the 1900s (99). It wasn’t until 1998 that the UK Prospective Diabetes study, which 
is a 10-year randomized controlled trial, that reinforces the effectiveness of metformin 
not only in controlling T2DM, but also in reducing risk of cardiovascular diseases and 
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all-cause mortality (100). As a result, metformin is now the first-line drug that is being 
used worldwide for treatment of T2DM, and is the most prescribed first line anti-diabetic 
drug for newly diagnosed T2DM patients due to its effectiveness in reducing hepatic 
gluconeogenesis and in increasing skeletal muscle glucose uptake. Although metformin 
has been used for more than 50 years with great efficacy, the exact molecular 
mechanisms of how the drug works still remain under debate.  
However, the current literature mostly agrees that metformin could work through 
transient inhibition of the mitochondrial respiratory chain complex I, thereby reducing 
the ratio of AMP: ATP (101). This effect then could stimulate the allosteric activation of 
AMPK by AMP, thereby increasing the activation/phosphorylation of AMPK by the 
upstream kinase, such as LKB1. Known to be a pleiotropic kinase, AMPK not only 
switches off anabolic pathways, but also switches on catabolic pathways. In fact, the 
glucose-lowering effect of metformin is due to its ability to suppresses the expression of 
gluconeogenic genes via AMPK interaction with several molecules such as SIRT1, CBP, 
SHP that could then disrupt the activities of transcriptional activators of gluconeogenic 
genes (102).     
 AMPK, other than regulating glucose metabolism, also plays a role in regulating 
lipid metabolism (103). For example, AMPK is able to directly phosphorylate ACC, and 
also is able to decrease liver X receptor-α (LXRα)-regulated expression of SREBP-1c, 
thus decreasing lipogenesis (104). This role of AMPK has also rendered the beneficial 
effect of metformin in decreasing hepatic steatosis. For example, treatment of ob/ob 
mice with metformin showed a marked decreased in liver size and hepatic steatosis level 
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(105). Also, in both rat hepatocytes (106) and human HepG2 cultures (107), metformin 
treatment leads to a decrease in hepatic ACC activation dependent on hepatic AMPK 
activation, as well as an increase in hepatic fatty acid oxidation (FAO). Furthermore, 
concurrent treatment with metformin and an AMPK inhibitor brings about an increase in 
ACC activity, along with attenuated metformin actions on suppressing hepatic 
lipogenesis and on increasing FAO (106). Consistently, metformin treatment 
significantly decreases the hepatic mRNA expressions for SREBP-1c and FAS, and 
concurrently increases AMPK activation (106).   
 Other than anti-steatosis effect, there is recent evidence that metformin could 
suppress liver inflammation (6), which is another important component in NAFLD. 
Although metformin was shown to decrease histological liver inflammation in mice 
induced with methionine-choline-deficient diet, the exact cellular mechanism is not very 
well-explained. Indeed, there is a lack of studies in the current literature that explains the 
cellular mechanisms of how metformin suppresses liver inflammation. Therefore, other 
than confirming the anti-hepatic steatosis effect of metformin, it is of particular interest 
to study how metformin affects the adipose tissue to indirectly improve liver steatosis 
and inflammation. In addition, the effects of how metformin affects macrophage status 
in mediating the inflammatory status of the liver will also be examined.  
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SUMMARY 
 NAFLD, a spectrum of liver metabolic diseases, is highly associated with obesity 
and insulin resistance, and is becoming the most common liver disease in the Western 
society. During the pathological state, several metabolic pathways including de novo 
lipogenesis, and FFA availability from the adipose tissue could be altered, thereby 
resulting in an increased liver fat accumulation. Chronic fat accumulation in the liver 
and pro-inflammatory mediators derived from adipose tissue could well contribute to the 
inflammatory progression of NAFLD, therefore, causing various complications such as 
NASH, fibrosis, and sometimes, carcinoma. Since there hasn’t been an effective 
pharmaceutical managing strategy, various efforts have been undergone to study the 
effects of different compounds on NAFLD. With regard to this, metformin is of 
particular interest in our lab because of its ability to target AMPK. Because of this, 
metformin is not only able to improve glucose and fat metabolism, but also potentially 
improve inflammatory status in various tissues such as the liver and adipose tissue. In 
the context of NAFLD, macrophages play important role in generating cross-talk to the 
parenchyma in a paracrine manner, thereby affecting the inflammatory status of the 
liver. Therefore, it is of particular interest to study the effects of metformin in mediating 
various cell populations such as the hepatocytes, macrophages, and adipose tissue in 
improving hepatic steatosis and liver inflammation. 
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CHAPTER III 
METFORMIN AMELIORATES HEPATIC STEATOSIS AND LIVER 
INFLAMMATION IN VIVO* 
INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is defined by fat deposition in 
hepatocytes (hepatic steatosis). In generally accepted concepts, NAFLD is comprised of 
simple steatosis, which may be benign, and non-alcoholic steatohepatitis (NASH), which 
is the advanced form of NAFLD. Simple steatosis progresses to NASH when the liver 
develops overt inflammation and necrotic damage that are not associated with alcohol 
consumption. It is now recognized that NASH is a leading causal factor of cirrhosis and 
hepatocellular carcinoma (19,108). Additionally, hepatic steatosis is a major contributor 
of dyslipidemia that works with or without insulin resistance to significantly increase the 
incidence of atherogenic cardiovascular diseases (109). Given this, a better 
understanding of how to reduce hepatic steatosis and how to decrease liver inflammation 
are of critical importance in effectively managing NAFLD and fatty liver-associated 
metabolic and inflammatory diseases.  
Because NAFLD is highly prevalent in obese populations (110), obesity-
associated insulin resistance is considered as a factor that critically contributes to the 
____________ 
* Reprinted with permission from Woo, S.-L., Xu, H., Li, H., Zhao, Y., et al. Metformin 
ameliorates hepatic steatosis and inflammation without altering adipose phenotype in 
diet-induced obesity. (2014) PLoS One 9, e91111 Copyright:  © 2014 Woo et al.  
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development of NAFLD. Mechanistically, insulin resistance at both hepatic and 
systemic levels, along with hyperinsulinemia, acts to increase the expression of genes for 
lipogenic enzymes such as acetyl-CoA carboxylase 1 (ACC1) and fatty acid synthase 
(FAS) (20,111) and to decrease the expression of genes for fatty acid oxidation including 
carnitine palmitoyltransferase 1a (CPT1a) (112). These changes, in turn, bring about 
hepatic steatosis, which is considered as the primary “hit”. As indicated by the results 
from cultured hepatocytes, chronic fat deposition could trigger the inflammatory 
responses, usually considered as the “second hit”, by excessive oxidation and 
peroxidation. As shown by Nakamura et al., palmitate accumulation in the hepatocytes 
could induce pro-inflammatory response through activation of JNK by increased reactive 
oxygen species (ROS) production (113). Activated JNK could phosphorylate c-Jun, 
which then forms the activator protein-1 (AP-1) transcription factor that could increase 
the expression of pro-inflammatory cytokines such as TNF-α, Il-6, etc. (61). Indeed, the 
JNK pathway has been implicated to contribute to the development of NASH (114). 
Other than triggering the JNK pathway, ROS is also known to be able to stimulate the 
NF-B (115), which is another transcription factor that increases production of pro-
inflammatory cytokines. As has been implicated, NF-B activation in the liver not only 
increases inflammatory status of the liver but also is responsible for the inflammatory 
progression of liver diseases such as liver injury, fibrosis, and hepatocellular carcinoma 
(116).   
Metformin is a widely used anti-diabetic medicine that effectively lowers plasma 
glucose levels primarily by decreasing hepatic glucose production (HGP) and by 
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improving lipid metabolism in both liver and muscle tissues (117-120). At the cellular 
level, metformin activates AMPK, which serves as a key mechanism by which 
metformin treatment brings about a wide range of metabolic benefits (121). Though, 
recent evidence also suggests that metformin is capable of inhibiting hepatic 
gluconeogenesis, a key flux whose increase contributes to elevation of HGP and 
hyperglycemia, through pathway(s) other than AMPK (122,123). Although the 
mechanisms underlying metformin actions are more complicated than what were thought 
before, there is accumulating evidence that demonstrates the beneficial effects of 
metformin treatment on improving hepatic steatosis and on inhibiting liver inflammation 
(7,124). However, the exact mechanisms, particularly the anti-inflammatory effect of 
metformin on the liver, is unclear. Accordingly, it was hypothesized that metformin not 
only protects against NAFLD through direct effects on liver metabolic response, but also 
through decreasing liver inflammatory responses associated with decreased in JNK and 
NF-B signaling.  
 
MATERIALS AND METHODS 
Animal experiments 
C57BL/6J mice were obtained from the Jackson Laboratory and maintained on a 
12:12-h light-dark cycle (lights on at 06:00). At 5 – 6 weeks of age, male mice were fed 
a high-fat diet (HFD, 60% fat calories, 20% protein calories, and 20% carbohydrate 
calories) for 12 weeks and treated with metformin (150 mg/kg body weight/d, solutions 
in PBS) or PBS via oral gavages for the last 4 weeks. As additional controls, gender- and 
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age-matched C57BL/6J mice were fed a low-fat diet (LFD, 10% fat calories, 20% 
protein calories, and 70% carbohydrate calories) for 12 weeks and treated with PBS for 
the last 4 weeks. Both diets are products of Research Diets, Inc (New Brunswick, NJ) 
and contain the same of amount of casein, L-cystein, cellulose, sucrose, soybean oil, and 
minerals. However, the HFD contains much more lard but none corn starch compared 
with the LFD. During the 12-week feeding/treatment period, body weight and food 
intake of the mice were recorded weekly. After the feeding/treatment regimen, mice 
were fasted for 4 hr before sacrifice for collection of blood and tissue samples 
(36,125,126). Epididymal, mesenteric, and perinephric fat depots were dissected and 
weighed as visceral fat content (36). Liver weight was also recorded. After weighing, 
part of epididymal fat was subjected to isolation of stromal vascular cells as described 
below. Additional adipose and liver tissue samples were either fixed and embedded for 
histological analyses (H&E staining) or frozen in liquid nitrogen and stored at – 80 C 
for further analyses (36,127). Some mice were fasted similarly and used for insulin and 
glucose tolerance tests as described below. All animals received human care and all 
study protocols were approved by the Institutional Animal Care and Use Committee of 
Texas A&M University. 
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Insulin and glucose tolerance tests 
Mice were fasted for 4 hr and received an intraperitoneal injection of insulin (1 
U/kg body weight) or D-glucose (2 g/kg body weight). For insulin tolerance tests, blood 
samples (5 l) were collected from the tail vein before and at 15, 30, 45, and 60 min 
after the bolus insulin injection. Similarly, for glucose tolerance tests, blood samples 
were collected from the tail vein before and at 30, 60, 90 and 120 min after the glucose 
bolus injection (128,129). The levels of plasma glucose were measured using an 
enzymatic assay kit (Sigma, St. Louis, MO). 
 
Oil-Red-O staining and immunohistochemical analyses  
Frozen liver sections were stained with Oil-Red-O as previously described (130). 
The paraffin-embedded liver and adipose tissue blocks were cut into sections of 5 µm 
thickness and stained for the expression of F4/80 with rabbit anti-F4/80 (1:100) (AbD 
Serotec, Raleigh, NC) (128).   
 
Western blots 
Lysates were prepared from frozen tissue samples and cultured cells using the 
lysis buffer containing 50 mm HEPES (pH 7.4), 1% Triton X-100, 50 mm sodium 
pyrophosphate, 0.1 m sodium fluoride, 10 mm EDTA, 10 mm sodium orthovanadate, 10 
μg/ml aprotinin, 10 μg/ml leupeptin, 2 mm benzamidine, and 2 mm 
phenylmethylsulfonyl fluoride. After protein electrophoresis and transfer, immunoblots 
were performed using rabbit anti-serum as primary antibody at a 1:1,000 dilution. The 
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blot was followed by a 1:10,000 dilution of goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody kit (Immobilon™ Western; EMD Millipore, Billerica, 
MA, USA) as previously described (36). GAPDH was used as a loading control. The 
maximum intensity of each band was quantified using ImageJ software. Ratios of P-
AMPK/AMPK, P-ACC/ACC, Pp46/p46, and Pp65/p65 were normalized to GAPDH and 
adjusted relative to the average of PBS-treated control, which was arbitrarily set as 1 
(AU). 
 
RNA isolation, reverse transcription, and real-time PCR 
The total RNA was isolated from frozen tissue samples and cultured/isolated 
cells. Reverse transcription was performed using the GoScript™ Reverse Transcription 
System (Promega) and real-time PCR analysis was performed using SYBR Green 
(LightCycler 480 system; Roche) (54,126,131). The mRNA levels were analyzed for 
ACC1, FAS, CPT1a, SREPB1c, IL-1, IL-6, TNF in tissue samples. A total of 0.1 μg 
RNA was used for the determination. Results were normalized to 18s ribosomal RNA as 
plotted as relative expression to the average of PBS-treated control, which was set as 1.   
 
Statistical methods 
  Numeric data are presented as means ± SE (standard error). Two-tailed Student’s 
t tests were used for statistical analyses. Differences were considered significant at the P 
< 0.05.  
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RESULTS  
Metformin treatment ameliorates HFD-induced systemic insulin resistance and 
glucose intolerance   
C57BL/6J mice were fed a high-fat diet (HFD) for 12 weeks to induce obesity 
(diet-induced obesity, DIO). Compared with age- and gender-matched mice that were 
fed a low-fat diet (LFD), HFD-fed and phosphate-buffered saline (PBS)-treated mice 
exhibited a marked increase in body weight (Figure 1 (A)), as well as overt hepatic 
steatosis and increased liver inflammatory responses (see below, Figures 2 and 3). These 
results demonstrate the establishment of NAFLD in obese mice. In addition, HFD-fed 
and PBS-treated mice displayed a significant increase in the severity of insulin resistance 
and glucose intolerance (Figure 1, (C) and (D)) compared with LFD-fed and PBS-treated 
mice. Upon treatment with metformin, body weight of HFD-fed mice remained the same 
compared with HFD-fed and PBS-treated mice. Also, metformin treatment did not alter 
food intake of HFD-fed mice (Figure 1 (B), HFD-Met vs. HFD-PBS). However, 
metformin-treated mice showed a significant decrease in the severity of HFD-induced 
insulin resistance and glucose intolerance (Figure 1, (C) and (D)), which were indicated 
by changes in plasma levels of glucose in response to a peritoneal injection of insulin 
and glucose, respectively. Thus, treatment with metformin ameliorates HFD-induced 
systemic insulin resistance and glucose intolerance without altering body weight in DIO 
mice.    
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Figure 1. Metformin treatment ameliorates HFD-induced insulin 
resistance and glucose intolerance. Male C57BL/6J mice, at 5–6 weeks of 
age, were fed a high-fat diet (HFD) and treated with metformin (Met, 150 
mg/kg body weight/d, in phosphate-buffered saline (PBS)) or PBS for the 
last 4 weeks of HFD feeding. As an additional control, gender- and age-
matched mice were fed a low-fat diet (LFD) for 12 weeks and treated only 
with PBS for the last 4 weeks. Data are means 6 SE, n = 6–10. (A) Body 
weight was monitored weekly during the feeding/treatment regimen. (B) 
Food intake was calculated based on food consumption per day per mouse. 
(C) Insulin tolerance tests (ITT). (D) Glucose tolerance tests (GTT). For C 
and D, mice were fasted for 4 hr and received an intraperitoneal injection of 
insulin (1 U/kg body weight) (C) or glucose (2 g/kg body weight) (D). *, 
P,0.05 and **, P,0.01 HFD-Met vs. HFD-PBS for the same time point (C and 
D). 
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Metformin treatment decreases HFD-induced hepatic steatosis and increases liver 
AMPK phosphorylation  
NAFLD is commonly associated with obesity. Consistent with increased body 
weight, liver weight of HFD-fed and PBS-treated mice was much greater than that of 
LFD-fed mice (Figure 2 (A)). Additionally, HFD-fed and PBS-treated mice displayed 
severe hepatic steatosis indicated by changes in liver sections stained with hematoxylin 
and eosin (H&E) and/or Oil-Red-O (Figure 2 (B)). Given this, HFD-fed mice, serving as 
a mouse model of NAFLD, were used to examine the therapeutic effects of metformin, 
as well as the underlying mechanisms. Compared with HFD-fed and PBS-treated mice, 
HFD-fed and metformin-treated mice exhibited a significant decrease in liver weight 
(Figure 2 (A)), which was accompanied by a marked decrease in the severity of hepatic 
steatosis (Figure 2 (B)). Thus, treatment with metformin effectively ameliorates hepatic 
steatosis in obese mice. We next examined changes in liver AMPK phosphorylation, 
which may underlie the beneficial effects of metformin. Compared with LFD-fed and 
PBS-treated mice, HFD-fed and PBS-treated mice showed a significant decrease in liver 
AMPK phosphorylation (Figure 2 (C)). This decrease was reversed by treatment with 
metformin as this was supported by the finding that liver AMPK phosphorylation in 
HFD-fed and metformin-treated mice was much greater than that in HFD-fed and PBS-
treated mice (Figure 2 (C)). Consistently, the phosphorylation of ACC, a substrate 
enzyme of AMPK, was decreased in HFD-fed and PBS-treated mice compared with that 
in LFD-fed mice. Upon treatment with metformin, liver ACC phosphorylation in HFD-
fed mice was significantly increased compared with that of HFD-fed and PBS-treated 
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mice (Figure 2 (C)). We also examined changes in the mRNA levels of key enzymes that 
critically control the development of hepatic steatosis from livers of HFD-fed mice. In 
terms of regulating hepatic gene expression, the effects of HFD feeding have been 
previously studied in rodents by a number of investigators. However, HFD feeding 
increases liver FAS mRNA levels when compared with a chow diet (132,133) and 
decreases liver FAS mRNA levels when compared with LFD feeding (134,135). 
Additionally, HFD feeding appears to have limited effects on liver expression of ACC 
and SREBP1c. In the presented study, we confirmed that HFD feeding decreased liver 
mRNA levels of FAS compared with LFD feeding. Meanwhile, HFD feeding did not 
significantly alter the mRNA levels of ACC and SREPBP1c. However, within all HFD-
fed mice, treatment with metformin caused a significant decrease in the mRNA levels of 
ACC1 and FAS compared with PBS (Figure 2 (D)). These results, together with 
decreased phosphorylation of liver ACC in metformin-treated mice, suggest a likely 
decrease in hepatic lipogenesis, which is consistent with the outcome of increased 
hepatic AMPK phosphorylation. Compared with LFD-fed and PBS-treated mice, HFD-
fed and PBS-treated mice also displayed a decrease in liver mRNA levels of CPT1a, a 
rate-determining enzyme that transfers long-chain fatty acids into mitochondria for 
oxidation. Within HFD-fed mice, treatment with metformin tended to increase liver 
mRNA levels of CPT1a, but the increase was not statistically significant. Collectively, 
these results suggest that metformin ameliorates HFD-induced hepatic steatosis, and this 
effect of metformin is associated with an increase in liver AMPK phosphorylation.   
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Figure 2. Metformin treatment ameliorates HFD-induced hepatic steatosis. 
Mice were treated as described in Figure 1. After the feeding/treatment regimen, 
mice were fasted for 4 hr prior to collection of tissue samples. (A) Liver weight (n 
= 6–10). (B) Liver histology. Top panels, H&E staining; bottom panels, Oil-Red-
O staining. For bar graph A, data are means ± SE, n = 6–8. †, P<0.05 and ††, 
P<0.01 HFD-PBS or HFD-Met vs. LFD-PBS (A); *, P<0.05 and **, P<0.01 
HFD-Met vs. HFD-PBS (A). 
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Metformin treatment inhibits HFD-induced liver inflammatory responses  
Inflammation is the key factor that drives the progression of simple steatosis to 
NASH. We examined the content of macrophages/Kupffer cells (F4/80+ cells) in livers 
of the mice. Unlike adipose tissue which displays a marked increase in macrophage 
infiltration in response to HFD feeding as established by many publications, livers of 
HFD-fed and PBS-treated mice contained fewer numbers of F4/80+ cells (Figure 4 (A), 
quantitative data not shown). Also, treatment with metformin tended to increase liver 
content of F4/80+ cells. These results suggest that liver content of F4/80+ cells is not an 
Figure 3. Metformin treatment increases liver AMPK phosphorylation in 
HFD-fed mice. (A) Liver AMPK signaling. Liver extracts were subjected to 
Western blot analyses. Ratios of phosphorylated AMPK to total AMPK (P-
AMPK/AMPK) and phosphorylated ACC to total ACC (P-ACC/ACC) were 
quantified using densitometry and normalized to GAPDH (AU, arbitrary unit). 
(B) Liver mRNA levels of key lipid metabolic enzymes (genes) were analyzed 
using real-time PCR. For bar graph A, data are means ± SE, n = 6–8. †, P<0.05 
and ††, P<0.01 HFD-PBS or HFD-Met vs. LFD-PBS (A and B); *, P<0.05 and 
**, P<0.01 HFD-Met vs. HFD-PBS (A and B). 
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ideal indicator of liver inflammatory responses. We then examined liver inflammatory 
signaling through JNK and NF-B p65 and quantified the mRNA levels of pro-
inflammatory cytokines to assess liver inflammatory responses. Compared with that in 
livers of LFD-fed and PBS-treated mice, the phosphorylation of JNK1 (p46) in livers of 
HFD-fed and PBS-treated mice was significantly increased (Figure 4 (B)). A similar 
trend was also observed in the phosphorylation of NF-B p65 (Ser536) in livers of HFD-
fed and PBS-treated mice compared with LFD-fed controls; although this trend did not 
reach statistical significance. Upon treatment with metformin, the phosphorylation of 
liver JNK1 (p46) was significantly decreased compared with that of HFD-fed and PBS-
treated mice (Figure 3 (B)). When liver mRNA levels of proinflammatory cytokines 
were examined, HFD-fed and PBS-treated mice displayed a significant increase in the 
mRNA levels of interleukin-6 (IL-6), a proinflammatory cytokine that is abundantly 
expressed in hepatocytes; although HFD-fed and PBS-treated mice showed a decrease in 
liver mRNA levels of IL-1 and tumor necrosis factor  (TNF) compared with LFD-
fed and PBS-treated mice. Within all HFD-fed mice, treatment with metformin 
significantly decreased liver mRNA levels of IL-6, as well as IL-1 and TNF 
compared with PBS (Figure 4 (C)). Together, these results suggest that metformin 
decreases liver inflammatory responses while improving hepatic steatosis in DIO mice.  
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Figure 4. Metformin treatment ameliorates HFD-induced liver inflammatory 
responses. Mice were treated as described in Figure 1. After the feeding/treatment 
regimen, mice were fasted for 4 hr prior to collection of tissue samples. (A) Liver 
sections were stained for F4/80+ cells. (B) Liver inflammatory signaling. Liver 
extracts were subjected to Western blot analyses. Ratios of phosphorylated JNK1 to 
total JNK1 (Pp46/p46) and phosphorylated NF-kB p65 to total p65 (Pp65/p65) were 
quantified using densitometry and normalized to GAPDH. (C) Liver mRNA levels 
of pro-inflammatory cytokines were analyzed using real-time PCR. For bar graphs 
(B and C), data are means ± SE, n = 6–8. †, P<0.05 and ††, P<0.01 HFD-PBS or 
HFD-Met vs. LFD-PBS; *, P<0.05 and **, P<0.01 HFD-Met vs. HFD-PBS. 
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DISCUSSION 
 On an HFD, C57BL/6J mice developed obesity-associated insulin resistance, as 
well as hepatic steatosis and inflammation. Accordingly, HFD-fed mice were used as a 
model of NAFLD to assess the therapeutic effects of metformin. Consistent with the 
results obtained from both human subjects and rodent models (7,124,136), metformin 
treatment not only improved HFD-induced systemic insulin resistance and glucose 
intolerance, but also brought about a marked decrease in the severity of HFD-induced 
hepatic steatosis and inflammation. 
 Metformin is considered as an activator of AMPK. The latter, when in active 
form(s), exhibits an anti-lipogenic effect through suppressing hepatic expression of 
lipogenic enzymes including ACC1 and FAS (130). In addition, active AMPK 
phosphorylates and inhibits ACC1/2 (137). This leads to a decrease in the production of 
malonyl-CoA, which in turn releases the inhibitory effect on CPT1a to favor fatty acid 
oxidation. In combination, these effects of active AMPK are thought to account, to a 
large extent, for metformin actions on reducing hepatic steatosis. In the in vivo study, 
changes in liver AMPK phosphorylation, indicative of AMPK activity, were positively 
correlated with the phosphorylation of liver ACC, which indicates decreased activity of 
ACC, and reversely correlated with the degree of hepatic steatosis and with changes in 
the mRNA levels of ACC1 and FAS. 
 The present study also suggests a potential link between AMPK and liver 
inflammation that is altered by metformin. In support of this, reversal of HFD-induced 
decrease in AMPK phosphorylation by metformin was accompanied by decreases in the 
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phosphorylation of liver JNK1 (p46) and in the mRNA levels of proinflammatory 
cytokines. This observation was consistent with the results of a recent study in which 
metformin decreased liver inflammatory responses in mice fed both a methionine- and 
choline-deficient (MCD) diet and an HFD (124). However, the study involving 
MCD/HFD-fed mice did not address how metformin suppresses liver inflammation, 
which could originate from hepatocyte fat deposition, macrophage/Kupffer cell pro-
inflammatory activation, and/or adipose tissue inflammation (54,138-140). And, these 
are studied and discussed further in the following chapters. 
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CHAPTER IV 
METFORMIN DOES NOT IMPROVE ADIPOSE TISSUE METABOLIC 
PHENOTYPE AND INFLAMMATORY STATUS* 
INTRODUCTION 
Adipose tissue dysfunction is an important characteristic of obesity that can 
complicate the existing comorbidities associated with obesity. Adipose tissue 
dysfunction has also been implicated in the development of NAFLD. Indeed, this role of 
dysfunctional adipose tissue is highlighted by the “second hit” hypothesis. In support of 
this, adipocyte-specific overexpression of monocyte chemoattractant protein-1 (MCP1), 
an inflammatory molecule up-regulated in adipose tissue of obese mice and human 
subjects, mediates the effect of adipose tissue inflammation to bring about an increase in 
hepatic triglyceride content (141). These results and many others suggest that 
dysfunctional adipose tissue contributes to hepatic steatosis by increasing the delivery of 
fatty acid flux to the liver (19) and by impairing liver insulin signaling through adipose 
tissue-driven inflammation (142,143).  
Metformin has been shown to be able to induce weight loss (i.e. adiposity) in 
both animals and humans (144-146), and this effect of metformin is found to be due to a 
reduction in food intake following metformin treatment. However, we do not exclude the 
__________ 
 
* Reprinted with permission from Woo, S.-L., Xu, H., Li, H., Zhao, Y., et al. Metformin 
ameliorates hepatic steatosis and inflammation without altering adipose phenotype in 
diet-induced obesity. (2014) PLoS One 9, e91111 Copyright:  © 2014 Woo et al.  
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possibility that metformin might act through different mechanisms other than reducing 
food intake. Considering that excessive adipose tissue contributes excess FFA and 
inflammatory mediators to the liver, causing NAFLD, we were interested in examining 
if metformin could act through a different mechanism, other than reducing food intake, 
to reduce adiposity thus, indirectly reducing the contribution of FFA and inflammatory 
mediators from adipose tissue to the liver during NAFLD. Therefore, using the adipose 
tissue collected from the DIO mice model in the previous chapter, we hypothesized that 
metformin treatment could decrease fat mass and the inflammatory status of adipose 
tissue through increasing activation of AMPK in adipose tissue.  
 
MATERIALS AND METHODS 
Animal experiments 
C57BL/6J mice were obtained from the Jackson Laboratory and maintained on a 
12:12-h light-dark cycle (lights on at 06:00). At 5 – 6 weeks of age, male mice were fed 
a high-fat diet (HFD, 60% fat calories, 20% protein calories, and 20% carbohydrate 
calories) for 12 weeks and treated with metformin (150 mg/kg body weight/d, solutions 
in PBS) or PBS via oral gavages for the last 4 weeks. As additional controls, gender- and 
age-matched C57BL/6J mice where fed a low-fat diet (LFD, 10% fat calories, 20% 
protein calories, and 70% carbohydrate calories) for 12 weeks and treated with PBS for 
the last 4 weeks. Both diets are products of Research Diets, Inc (New Brunswick, NJ) 
and contain the same of amount of casein, L-cystein, cellulose, sucrose, soybean oil, and 
minerals. However, the HFD contains much more lard but none corn starch compared 
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with the LFD. During the 12-week feeding/treatment period, body weight and food 
intake of the mice were recorded weekly. After the feeding/treatment regimen, mice 
were fasted for 4 hr before sacrifice for collection of blood and tissue samples 
(36,125,126). Epididymal, mesenteric, and perinephric fat depots were dissected and 
weighed as visceral fat content (36). Liver weight was also recorded. After weighing, 
part of epididymal fat was subjected to isolation of stromal vascular cells as described 
below. Additional adipose and liver tissue samples were either fixed and embedded for 
histological analyses (H&E staining) or frozen in liquid nitrogen and stored at – 80 C 
for further analyses (36,127). All animals received human care and all study protocols 
were approved by the Institutional Animal Care and Use Committee of Texas A&M 
University. 
 
Isolation of stromal vascular cells from adipose tissue 
Adipose tissue stromal vascular cells (SVC) were isolated using the collagenase 
digestion method as previously described (128,147). After digestion and centrifugation, 
the pelleted cells were collected as SVC and subjected to FACS analyses.    
 
Flow cytometry analysis 
Adipose tissue SVC were stained with fluorescence-tagged antibodies: anti-
F4/80, anti-CD11b for macrophages, and anti-CD11c and anti-CD206 for macrophage 
inflammatory status as previously described (148), and subjected to FACS analyses 
using BD FACSAria II flow cytometer (BD Biosciences, San Jose, California, USA) that 
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is operated by Texas A&M Health Science Center College of Medicine Cell Analysis 
Facility. 
 
Western blots 
Lysates were prepared from frozen tissue samples and cultured cells using the 
lysis buffer containing 50 mm HEPES (pH 7.4), 1% Triton X-100, 50 mm sodium 
pyrophosphate, 0.1 m sodium fluoride, 10 mm EDTA, 10 mm sodium orthovanadate, 10 
μg/ml aprotinin, 10 μg/ml leupeptin, 2 mm benzamidine, and 2 mm 
phenylmethylsulfonyl fluoride. After protein electrophoresis and transfer, immunoblots 
were performed using rabbit anti-serum as primary antibody at a 1:1,000 dilution. The 
blot was followed by a 1:10,000 dilution of goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody kit (Immobilon™ Western; EMD Millipore, Billerica, 
MA, USA) as previously described (36). GAPDH was used as a loading control. The 
maximum intensity of each band was quantified using ImageJ software. Ratios of P-
AMPK/AMPK, Pp46/p46, and Pp65/p65 were normalized to GAPDH and adjusted 
relative to the average of PBS-treated control, which was arbitrarily set as 1 (AU). 
 
RNA isolation, reverse transcription, and real-time PCR 
The total RNA was isolated from frozen tissue samples and cultured/isolated 
cells. Reverse transcription was performed using the GoScript™ Reverse Transcription 
System (Promega) and real-time PCR analysis was performed using SYBR Green 
(LightCycler 480 system; Roche) (54,126,131). The mRNA levels were analyzed for 
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IL-1, IL-6, TNF, arginase 1, adiponectin, and/or resistin in tissue samples. A total of 
0.1 μg RNA was used for the determination. Results were normalized to 18s ribosomal 
RNA as plotted as relative expression to the average of PBS-treated control, which was 
set as 1. 
   
Statistical methods 
  Numeric data are presented as means ± SE (standard error). Two-tailed Student’s 
t tests were used for statistical analyses. Differences were considered significant at the P 
< 0.05.   
 
RESULTS 
Metformin treatment does not alter HFD-induced adiposity  
  During obesity, dysfunctional adipose tissue critically contributes to the 
development of NAFLD (143). We examined changes in adipose tissue phenotype. 
Consistent with DIO, all HFD-fed mice displayed a marked increase in visceral fat mass 
compared with LFD-fed mice (Figure 5 (A)). Following treatment with metformin, 
HFD-fed mice did not display significant changes in visceral fat mass compared with 
HFD-fed and PBS-treated mice (Figure 5 (A)). Additionally, the size of adipocytes in 
HFD-fed and metformin-treated mice did not differ from that in HFD-fed and PBS-
treated mice indicated by adipose tissue histology (Figure 5 (B)). Thus, treatment with 
metformin did not alter HFD-induced adiposity.  
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Figure 5. Metformin treatment does not alter HFD-induced adiposity. 
Mice were treated as described in Figure 1. After the feeding/treatment 
regimen, mice were fasted for 4 hr prior to collection of tissue samples. (A) 
Fat mass (Epididymal, perinephric, mesenteric, and visceral fat mass) (n = 6-
10). (B) Adipose tissue histology (H&E staining). For bar graph (A), data are 
means ± SE. ϯ, P < 0.05 and ϯϯ, P < 0.01 HFD-PBS vs. LFD-PBS. 
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Metformin treatment does not alter HFD-induced adipose tissue inflammatory 
responses 
  We next examined adipose tissue inflammatory responses. As indicated by 
percentages of mature macrophages (F4/80+ CD11b+ cells) from the isolated adipose 
tissue stromal vascular cells (Figure 6 (A)), adipose tissue macrophage infiltration in 
HFD-fed and PBS-treated mice was markedly increased compared with that in LFD-fed 
and PBS-treated mice (Figure 6 (B)). However, within HFD-fed mice, treatment with 
metformin did not significantly alter adipose tissue macrophage infiltration (Figure 6 (B) 
and 6 (C)). These results were consistent with the finding that adipose tissue content of 
F4/80+ cells in HFD-fed and metformin-treated mice did not differ from that in HFD-fed 
and PBS-treated mice (Figure 6 (A)). Further analyses indicated that the percentages of 
pro-inflammatory macrophages (F4/80+ CD11b+ CD11c+ CD206– cells) among mature 
adipose tissue macrophages in HFD-fed and metformin-treated mice also did not differ 
from those in HFD-fed and PBS-treated mice (data not shown). 
  Unlike changes in liver AMPK signaling, adipose tissue AMPK signaling 
(phosphorylation) was not altered by metformin. Additionally, metformin treatment did 
not alter adipose tissue inflammatory signaling, indicated by the phosphorylation of 
JNK1 (p46) and NF-B p65 (Ser536) (Figure 7 (A)). When pro-inflammatory cytokine 
expression was examined for HFD-fed mice, treatment with metformin did not 
significantly alter adipose tissue mRNA levels of IL-1, IL-6, and TNF (Figure 7 (B)), 
as well as mRNA levels of arginase 1, adiponectin, and resistin, which all are related to 
adipose tissue inflammation and function. Therefore, treatment with metformin for 4 
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weeks appears to have limited effects on altering adipose tissue phenotype in obese 
mice, indicated by adiposity and inflammatory responses.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Metformin treatment does not alter HFD-induced adipose tissue 
inflammation. (A) Adipose tissue sections were stained for F4/80+ cells. (B) 
Adipose tissue macrophage infiltration. (C) Percentages of mature macrophages 
(F4/80+ CD11b+ cells) in adipose tissue stromal cells were calculated using FACS 
analyses (n = 4 – 6). For bar graph (C), data are means ± SE. 
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Figure 7. Metformin treatment does not alter adipose tissue AMPK 
status and inflammation. (A) Adipose tissue AMPK signaling and 
inflammatory signaling were examined using Western blot analyses (n 
= 4 – 6). (B) The mRNA levels of adipose genes were quantified using 
real-time PCR (n = 4 – 6). For bar graph (B), data are means ± SE. 
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DISCUSSION 
As illustrated by widely accepted concepts, dysfunctional adipose tissue during 
obesity contributes to the pathogenesis of NAFLD by increasing the delivery of fatty 
acids and inflammatory mediators to the liver to exacerbate hepatic fat deposition and 
inflammatory responses. Because of this, we also postulated that improved adipose 
tissue phenotype would contribute to the anti-NAFLD effect of metformin. However, 
this was not the case. In the present study, adipose tissue, unlike the liver, did not 
respond to metformin treatment. Notably, HFD-induced adiposity and adipose tissue 
inflammation in metformin-treated mice did not differ from those in PBS-treated control 
mice. The underlying mechanisms remained to be elucidated, but may be attributable to 
the effect that metformin treatment did not alter adipose tissue AMPK phosphorylation. 
Indeed, metformin actions on adipose tissue phenotype remain controversial. While 
metformin is shown to reduce body weight (adiposity) in both human and rodent models, 
a number of papers also demonstrate that metformin does not alter body weight, in 
particular in rodents fed an HFD (119,149,150). Additionally, the weight-loss effect of 
metformin is tied closely to a decrease in food intake, leading to a question of whether or 
not metformin directly acts on adipose tissue. Considering this, the beneficial effects of 
metformin on features of NAFLD appear to be due largely to the direct effects of 
metformin on the liver. What should also be mentioned is that metformin is capable of 
countering insulin-induced suppression of muscle fatty acid oxidation and promoting 
triglyceride storage in skeletal muscle (151). These effects may also contribute to the 
beneficial effects of metformin on features of NAFLD. 
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CHAPTER V 
METFORMIN HAS A DIRECT EFFECT ON HEPATOCYTES AND 
MACROPHAGES IN IMPROVING LIPID METABOLISM AND LIVER 
INFLAMMATION* 
INTRODUCTION 
 Liver inflammation plays an important role in the progression of NAFLD. 
Among the cell population in the liver, immune cells such as Kupffer cells that reside 
within the liver are highly involved in the inflammatory progression of NAFLD. 
Excessive activation of Kupffer cells could affect not only the non-parenchyma cells, but 
also the parenchyma, thereby regulating their function and phenotype (152). Therefore, 
depending on the source of stimuli, an altered Kupffer cell phenotype is critical in 
contributing towards various acute and chronic liver diseases. For example, in an obese 
environment, increased exposure of LPS and FFAs could induce a pro-inflammatory 
phenotype of macrophages, producing high levels of TNF-α that could increase 
hepatotoxicity and making the hepatocyte more susceptible to necrosis (153,154). 
Alternatively, Kupffer cells that were alternatively activated with IL-4 demonstrated 
improved hepatic function (155).  
In the recent years, increasing studies have emphasized the role of Kupffer cells  
__________ 
 
* Reprinted with permission from Woo, S.-L., Xu, H., Li, H., Zhao, Y., et al. Metformin 
ameliorates hepatic steatosis and inflammation without altering adipose phenotype in 
diet-induced obesity. (2014) PLoS One 9, e91111 Copyright:  © 2014 Woo et al.  
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in the pathogenesis of NAFLD. Studies that selectively deplete Kupffer cells by 
administration of gadolinium chloride (GdCl3), a rare metal that can inhibit mononuclear 
phagocytic system hence killing Kupffer cells, could protect against liver injury induced 
by multiple sources including alcohol (156), thioacetamide (157), ischemia (158), and 
most importantly, insulin resistance and hepatic steatosis (159). Likewise, depletion of 
Kupffer cells using chlodronate markedly blunted methionine/choline deficient (MCD) 
diet-induced steatohepatitis evidenced by histological improvement of the liver.  
 From the result of Chapter III, we demonstrated that metformin has a direct 
effect in suppressing liver inflammation. Therefore, in this chapter, we further 
hypothesized that this anti-inflammatory property of metformin in the liver not only 
direct targets hepatocytes, but also targets Kupffer cells in suppressing liver 
inflammation.  
 
MATERIALS AND METHODS 
Cell culture and treatment  
H4IIE cells (rat hepatoma cells) were maintained in high glucose Dulbecco’s 
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 100 
units/ml penicillin and 100 g/l streptomycin as previously described (54,139). At 80% 
confluence, H4IIE cells were treated with metformin (500 μM) or PBS in the presence or 
absence of palmitate (250 μM) for 24 hr to induce fat deposition. To examine lipid 
accumulation, the treated hepatocytes were stained with Oil-Red-O for the last 1 hr. To 
determine changes in hepatocyte AMPK and inflammatory signaling, metformin- or 
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PBS-treated cells were supplemented with or without LPS (100 ng/ml) for 30 min prior 
to harvest. Cell lysates were prepared and used to measure the levels of AMPK, JNK1, 
NF-B p65, phospho-AMPK, phospho-JNK1, and phospho-p65 (Ser536) using Western 
blot analyses. To analyze hepatocyte gene expression, the total RNA was prepared from 
metformin- or PBS-treated cells and subjected to reverse transcription and real-time 
PCR.  
Additional to hepatocytes, macrophages were also used to address a direct anti-
inflammatory effect of metformin. Briefly, bone marrow cells were isolated from the 
tibias and femurs of chow diet-fed C57BL/6J mice as previously described (160). After 
differentiation with Iscove's modified Dulbecco’s medium (IMDM) containing 10% fetal 
bovine serum and 15% L929 culture supernatant for 8 days, bone marrow-derived 
macrophages (BMDM) were treated with metformin (500 μM) or PBS for 24 hr in the 
presence or absence of LPS (100 ng/ml) for the last 30 min. Cell lysates were prepared 
and used to examine the inflammatory signaling using Western blot analyses. Some cells 
were treated with or without LPS at the same dose for 6 hr prior to harvest of RNA 
samples.   
 
Oil-Red-O staining  
Frozen liver sections were stained with Oil-Red-O as previously described (130).  
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Western blots 
Lysates were prepared from frozen tissue samples and cultured cells using the 
lysis buffer containing 50 mm HEPES (pH 7.4), 1% Triton X-100, 50 mm sodium 
pyrophosphate, 0.1 m sodium fluoride, 10 mm EDTA, 10 mm sodium orthovanadate, 10 
μg/ml aprotinin, 10 μg/ml leupeptin, 2 mm benzamidine, and 2 mm 
phenylmethylsulfonyl fluoride. After protein electrophoresis and transfer, immunoblots 
were performed using rabbit anti-serum as primary antibody at a 1:1,000 dilution. The 
blot was followed by a 1:10,000 dilution of goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody kit (Immobilon™ Western; EMD Millipore, Billerica, 
MA, USA) as previously described (36). GAPDH was used as a loading control. The 
maximum intensity of each band was quantified using ImageJ software. Ratios of P-
AMPK/AMPK, P-ACC/ACC, Pp46/p46, and Pp65/p65 were normalized to GAPDH and 
adjusted relative to the average of PBS-treated control, which was arbitrarily set as 1 
(AU). 
 
RNA isolation, reverse transcription, and real-time PCR 
The total RNA was isolated from cultured/isolated cells. Reverse transcription 
was performed using the GoScript™ Reverse Transcription System (Promega) and real-
time PCR analysis was performed using SYBR Green (LightCycler 480 system; 
Roche) (54,126,131). The mRNA levels were analyzed for ACC1, FAS, CPT1a, 
SREPB1c, IL-1, IL-6, TNF, in cell samples. A total of 0.1 μg RNA was used for the 
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determination. Results were normalized to 18s ribosomal RNA as plotted as relative 
expression to the average of PBS-treated control, which was set as 1.   
 
RESULTS 
Metformin treatment inhibits hepatocyte fat deposition and lipogenic events 
As indicated by the results listed above (Figures 2 – 4), the liver is the primary 
target through which metformin ameliorates NAFLD in obese mice. We next examined 
the direct effects of metformin on metabolic and inflammatory responses in H4IIE cells, 
a rat hepatoma cell line commonly used as a cell model of NAFLD (54,140). As shown 
in the Oil Red O staining (Figure 8 (A)), treatment of H4IIE cells with palmitate induced 
a significant increase in fat deposition in the absence of metformin. This effect of 
palmitate, however, was partially blunted by metformin treatment, indicating a direct 
effect of metformin on inhibiting hepatocyte fat deposition. Consistent with changes in 
hepatocyte fat deposition, the mRNA levels of ACC1 and FAS in palmitate-treated 
H4IIE cells were significantly increased compared with those in control cells (Figure 8 
(B)). Following treatment with metformin, the stimulatory effect of palmitate on the 
expression of ACC1 and FAS was blunted (Figure 8 (B)). However, CPT1a mRNA 
levels were not significantly altered by palmitate in the absence or presence of 
metformin in H4IIE cells (Figure 8 (B)). 
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Figure 8. Metformin treatment blunts hepatocyte fat 
deposition. (A) Hepatocyte fat deposition. Bottom panels, 
cells were incubated with palmitate (Pal). (B) Hepatocyte 
mRNA levels were quantified using real-time PCR. For A 
and B, H4IIE cells were treated with metformin (500 μM) or 
PBS in the presence of palmitate (250 μM) or bovine serum 
albumin (BSA) for 24 hr (B) and stained with Oil-Red-O for 
the last 1 hr (A). For bar graphs (B), data are means ± SE, n 
= 6 – 8. †, P < 0.05 and ††, P < 0.01 Pal + PBS vs. BSA + 
PBS (B); *, P < 0.05 and **, P < 0.01 Pal + Met vs. Pal + 
PBS (B). 
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Metformin treatment inhibits hepatocyte inflammatory signaling while increases 
AMPK activation 
We examined AMPK signaling and inflammatory signaling in H4IIE cells. 
Compared with that in cells treated with control (in the absence of metformin and 
lipopolysaccharide (LPS)), the phosphorylation of AMPK was increased in metformin-
treated cells (in the absence of LPS) (Figure 9). In the presence of LPS alone, AMPK 
phosphorylation was decreased compared with that in control cells (in the absence of 
metformin and LPS), and this decrease was partially reversed by treatment with 
metformin. When inflammatory signaling was examined, metformin treatment did not 
significantly alter the phosphorylation of JNK1 (p46) and NF-B p65 under the basal 
conditions (in the absence of LPS). However, metformin treatment significantly blunted 
the effect of LPS on increasing hepatocyte phosphorylation of JNK1 (p46) and NF-B 
p65 compared with that in control (PBS)-treated hepatocytes. We also examined the 
mRNA levels of proinflammatory cytokines. Compared with the control, the mRNA 
levels of IL-6 were increased in palmitate-treated H4IIE cells. This stimulatory effect of 
palmitate was completely blunted by treatment with metformin (Figure 8 (B)).  
Together, these results suggest that metformin directly decreases hepatocyte fat 
deposition and suppresses hepatocyte inflammatory responses.  
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Figure 9. Metformin treatment increases AMPK phosphorylation, and 
decreases inflammatory responses in hepatocytes. Hepatocyte AMPK 
signaling and inflammatory signaling were examined using Western blot 
analyses. H4IIE cells were treated with metformin (500 μM) or PBS for 24 hr in 
the presence or absence of LPS (100 ng/ml) for the last 30 min. Data are means ± 
SE, n = 6 – 8. †, P < 0.05 and ††, P < 0.01 LPS vs. PBS (without LPS) under the 
same condition (with or without Met); *, P < 0.05 and **, P < 0.01 Met vs. PBS 
(without Met) under the same condition (with or without LPS). 
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Metformin treatment suppresses macrophage pro-inflammatory activation 
Macrophages/Kupffer cells play a critical role in controlling the development of 
hepatic steatosis and inflammation (138). We examined a direct effect of metformin on 
macrophage pro-inflammatory activation. In the absence of metformin, bone marrow-
derived macrophages (BMDM) exhibited a significant increase in the phosphorylation of 
both JNK1 (p46) and NF-B p65 (Ser536) in response to LPS stimulation (Figure 10 
(A)), indicating LPS induction of macrophage pro-inflammatory activation. However, 
upon treatment with metformin, the effect of LPS on inducing the phosphorylation of 
JNK1 (p46) and NF-B p65 (Ser536) was partially blunted. When macrophage 
expression of pro-inflammatory cytokines was analyzed, the mRNA levels of IL-1, IL-
6, and TNF were markedly increased in control (PBS)-treated BMDM after LPS 
stimulation. However, in metformin-treated macrophages, the effect of LPS on 
increasing pro-inflammatory cytokine mRNA levels were significantly lessened (Figure 
10 (B)). Together, these results suggest that metformin has a direct effect on inhibiting 
macrophage pro-inflammatory activation.    
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Figure 10. Metformin treatment suppresses macrophage 
pro-inflammatory activation. Bone marrow-derived 
macrophages were treated with metformin (500 μM) or PBS for 
24 hr in the presence or absence of LPS (100 ng/ml) for the last 
30 min (A) or 6 hr (B). (A) Macrophage inflammatory signaling 
was examined using Western blot analyses. (B) Macrophage 
mRNA levels of proinflammatory cytokines were quantified 
using real-time PCR. For bar graphs (A and B), data are means ± 
SE, n = 4 – 6. ††, P < 0.01 LPS vs. PBS (without LPS) in the 
absence of metformin (A); **, P < 0.01 Met vs. PBS (without 
metformin) in the presence of LPS (A) or Met + LPS vs. PBS + 
LPS (B).   
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DISCUSSION 
By using an in vitro study, we were able to separately confirm that metformin not 
only could directly improve lipid metabolism and inflammation in hepatocytes, but also 
directly decrease macrophage inflammation. This could reflect the efficacy of metformin 
in decreasing hepatic steatosis and liver inflammation (by having direct effects on 
hepatocytes and macrophages, possibly Kupffer cells) shown in the in vivo study above. 
However, due to the fact that the macrophages in this in vitro study were not isolated 
from the liver, strictly speaking, the liver improving effect of metformin could not be 
claimed as improving effect in Kupffer cells in the current in vivo study. However, 
considering macrophages are of myeloid lineage, it could be assumed that metformin 
would have similar effects in Kupffer cells. 
In addition, by comparing the in vitro study in this chapter and the in vivo study 
of Chapter IV, metformin treatment decreases macrophage inflammation in vitro but did 
not alter the inflammatory status of adipose tissue macrophages in vivo. Additional to 
adipose tissue inflammatory status, adiposity of HFD-fed mice was also not reduced by 
metformin in the present study. When adipose and liver tissues were compared, adipose 
tissue macrophages interacted with a highly pro-inflammatory local environment likely 
due to excessive fat deposition whereas liver macrophages/Kupffer cells did not. 
Considering this, it is also possible that a potential anti-inflammatory action of 
metformin on adipose tissue macrophages was offset by the pro-inflammatory effects of 
adipocyte-derived factors in particular saturated fatty acids (161). However, this point 
needs to be further validated. In addition, given that metformin did not alter adipose 
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tissue AMPK, it is also possible that the treatment regimen used by the present study 
was not sufficient enough for metformin to be effective in adipose tissue. To verify this, 
future studies are required to include a relative long period of time and/or a higher dose 
for metformin treatment. Anyhow, from the presented studies, it appears to be clear that 
metformin primarily targets the liver to improve features of NAFLD and this effect of 
metformin is independent of adipose tissue phenotype.   
62 
 
CHAPTER VI 
METFORMIN ACTION ON IMPROVING NAFLD INVOLVES ACTIVATION 
OF AMPK IN HEPATOCYTES AND/OR MACROPHAGES 
INTRODUCTION  
AMPK is involved in glucose, lipid and protein metabolism, and is crucial in 
regulating the homeostasis of energy balance. It was originally discovered by its ability 
to inhibit fatty acid synthesis (92) and cholesterol synthesis (91) through 
phosphorylation of both ACC, involved in lipogenesis, and HMG-CoA reductase, 
involved in cholesterol synthesis, respectively. Extensive studies have then showed that 
AMPK plays more roles in human metabolism and diseased states than just lipid 
metabolism (103). Because AMPK is able to regulate hepatic lipogenesis directly 
through phosphorylation of SREBP-1c, thus to reduce the proteolytic cleavage and 
nuclear translocation of SREBP-1c, and indirectly through inhibiting SREBP-1c 
expression via the LXR/RXR pathway, numerous studies have confirmed that during 
NAFLD, AMPK is dysregulated, causing an increase in hepatic lipogenesis, thereby 
hepatic steatosis (162-164).  One very good example is that liver AMPK activity was 
decreased associated with an increase in hepatic steatosis in obese, NAFLD mice 
induced with a HFD (165). AMPK activators such as metformin and AICAR protected 
against hepatic steatosis through decreasing SREBP-1c activity in experimental models 
(107,166). 
 Other than its role in lipid metabolism, AMPK has been increasingly shown to 
downregulate inflammation in several disease states such as acute and chronic colitis 
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(167), inflammation in cystic fibrosis (168), autoimmune encephalomyelitis (169), etc.  
More importantly, it has been demonstrated that AMPK activity is negatively associated 
with inflammatory markers in human adipose tissue (170). Numerous studies have then 
revealed that the anti-inflammatory action upon AMPK stimulation may be due to the 
upregulation of sirtuin 1 (SIRT1), PGC-1α, FOXOs, and p53, thereby ultimately 
downregulating the NF-B-associated inflammatory response (171). However, limited 
studies have addressed the role of the anti-inflammatory effects of AMPK in the liver, 
though, a recent study have shown that pharmacological activation of AMPK could lead 
to suppression of inflammatory response in human hepatocyte cell line (172). It is also 
worth mentioning that a recent study has also shown that AMPK is able to regulate 
macrophage polarization to an anti-inflammatory phenotype under the stimulation of 
LPS (97).  
 From the result of Chapter V, we demonstrated that metformin has: (1) a direct 
effect on hepatocytes in decreasing hepatic steatosis by improving lipid metabolism, (2) 
a direct effect on hepatocytes and macrophages in decreasing liver inflammation. And, 
these effects were associated with an increase in AMPK activation. Therefore, in this 
chapter, we are interested in confirming if AMPK is necessary for the anti-inflammatory 
effect of metformin in decreasing liver inflammation.   
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MATERIALS AND METHODS  
Cell culture and treatment 
Primary hepatocytes were isolated as previously described (54,75). After 
attachment, primary hepatocytes were pretreated with AMPK inhibitor (compound C, 20 
µM) and then supplemented with metformin (500 μM) or PBS in the presence or 
absence of palmitate (250 μM) for 24 hr to induce fat deposition. To examine lipid 
accumulation, the treated hepatocytes were stained with Oil-Red-O for the last 1 hr. 
Additional primary mouse hepatocytes were pretreated with AMPK inhibitor (compound 
C, 20 µM) for 30 minutes and then supplemented with metformin (500 µM) or PBS for 
24 hr to examine if AMPK is necessary for the action of metformin. Cell lysates were 
prepared and used to measure the levels of AMPK, ACC, phospho-AMPK, phospho-
ACC using Western blot analyses. 
Additional to hepatocytes, a co-culture of primary mouse hepatocytes and bone 
marrow-derived macrophages were used to examine the cross-talk between hepatocytes 
and macrophages and the involvement of AMPK. Bone marrow cells were isolated from 
the tibias and femurs of chow diet-fed myeloid-specific deletion of α1AMPK mice as 
previously described (160), and differentiated with Iscove's modified Dulbecco’s 
medium (IMDM) containing 10% fetal bovine serum and 15% L929 culture supernatant 
for 6 days. Subsequently, isolated primary mouse hepatocytes from C57BL/6J mice 
(WT) were added to the macrophage culture in the ratio of 10:1. On day 7, the co-
cultured hepatocytes and macrophages were treated with metformin (500 μM) or PBS 
for 24 hr in the presence or absence of LPS (100 ng/ml) for the last 30 min. Cell lysates 
65 
 
were prepared and used to measure the levels of JNK, NF-B p65, phospho-JNK, and 
phospho-p65 (Ser536) using Western blot analyses. 
To verify the deletion of α1AMPK, additional bone marrow cells were isolated 
from tibias and femur of chow diet-fed myeloid-specific deletion of α1AMPK mice, and 
differentiated for 6 days. On day 7, macrophages were harvested and used to measure 
the level of AMPK. 
 
Western blots 
Lysates were prepared from frozen tissue samples and cultured cells using the 
lysis buffer containing 50 mm HEPES (pH 7.4), 1% Triton X-100, 50 mm sodium 
pyrophosphate, 0.1 m sodium fluoride, 10 mm EDTA, 10 mm sodium orthovanadate, 10 
μg/ml aprotinin, 10 μg/ml leupeptin, 2 mm benzamidine, and 2 mm 
phenylmethylsulfonyl fluoride. After protein electrophoresis and transfer, immunoblots 
were performed using rabbit anti-serum as primary antibody at a 1:1,000 dilution. The 
blot was followed by a 1:10,000 dilution of goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody kit (Immobilon™ Western; EMD Millipore, Billerica, 
MA, USA) as previously described (36). GAPDH was used as a loading control. The 
maximum intensity of each band was quantified using ImageJ software. Ratios of P-
AMPK/AMPK, P-ACC/ACC, Pp46/p46, and Pp65/p65 were normalized to GAPDH and 
adjusted relative to the average of PBS-treated control, which was arbitrarily set as 1 
(AU). 
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RESULTS 
AMPK is partly required for anti-steatosis effect of metformin 
 As previously indicated (Figure 2, 3), metformin treatment in HFD-fed 
C57BL/6J mice resulted in a decrease in hepatic steatosis and is associated with AMPK 
activation. In addition, in vitro study (Figure 8, 9) also confirmed the direct effect of 
metformin on hepatocytes in decreasing fat accumulation associated with AMPK 
activation. We next examined if AMPK is necessary for the anti-steatosis effect of 
metformin in primary mouse hepatocytes. In the absence of metformin, treatment of 
primary mouse hepatocytes with palmitate induced a significant increase in fat 
deposition (Figure 11 (A)). Similar to the result obtained in H4IIE cells (Figure 8), 
metformin treatment partially blunted the effect of palmitate-induced lipid accumulation. 
However, pretreatment of compound C (CC) abolished the anti-steatosis effect of 
metformin as shown by the Oil Red O staining (Figure 11 (A)).  
To confirm if CC effectively inhibited the activation of AMPK, we examined 
AMPK signaling in primary mouse hepatocytes. Compared with that in cells treated with 
control (in the absence of metformin and CC), the phosphorylation of AMPK was 
increased in metformin-treated cells (in the absence of CC) (Figure 11 (B)). When cells 
are pretreated with CC, AMPK phosphorylation was not altered compared with that in 
control cells (in the absence of metformin and CC). However, upon metformin treatment 
(cells pretreated with CC), the AMPK phosphorylation paradoxically increased 
compared with that in the control cells (in the presence of metformin alone) (Figure 11 
(B)). To confirm if our pretreatment of CC increases AMPK activity, we examined the 
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phosphorylation of ACC, a substrate of AMPK. Compared with that in cells treated with 
control (in the absence of metformin and CC), the phosphorylation of ACC was 
increased in metformin-treated cells (in the absence of CC) (Figure 11 (B)). However, 
when cells are pretreated with CC (in the absence of metformin), ACC phosphorylation 
was decreased compared with that in control cells (in the absence of metformin and CC). 
Similarly, pretreatment of CC (in the presence of metformin) resulted in a decreased in 
ACC phosphorylation compared with that in cells not treated with CC (in the presence of 
metformin) (Figure 11 (B)).  
 These results indicated that while pretreatment of CC paradoxically resulted in 
increased AMPK phosphorylation, this pretreatment of CC, however, resulted in a 
decrease in phosphorylation of ACC, thus increased activation of ACC, which could 
explain the increased in lipid accumulation upon pretreatment of CC as seen in the Oil 
Red O staining.  
 
 Macrophage AMPK is important in the anti-inflammatory action of metformin 
 Knowing that macrophages play important role in regulating liver inflammatory 
status, we examined the importance of AMPK in regulating the inflammatory response 
of macrophages, and how this will affect the inflammatory status of hepatocytes. We 
incubated bone-marrow derived macrophages (BMDMs) isolated from myeloid-specific 
deletion of α1AMPK mice, and then co-cultured with primary mouse hepatocyte from 
C57BL/6J mice (WT). As shown in Figure 12, α1AMPK deletion in macrophages was 
being verified. Therefore, the BMDMs and hepatocytes are co-cultured in a ratio of 1:10 
68 
 
in order to observe how metformin affect the inflammatory status of hepatocytes via 
regulating macrophage inflammation in the absence of AMPK. In the absence of 
metformin, the WT hepatocytes / WT macrophages co-culture exhibited a significant 
increase in the phosphorylation of JNK 1 (p46) and NF-ĸB p65 (Ser536) in response to 
LPS stimulation (Figure 13 (A)), indicating LPS induction of pro-inflammatory 
activation. Upon treatment with metformin, the effect of LPS on inducing the 
phosphorylation of JNK1 (p46) and NF-ĸB p65 (Ser536) was partially blunted. In the 
absence of metformin, the WT hepatocytes / α1AMPK-/- macrophages co-culture 
exhibited increase in the phosphorylation of JNK1 (p46) but not NF-ĸB p65 (Ser536) 
compared to that of the WT hepatocytes / WT macrophages co-culture. This increase in 
JNK 1 (p46) phosphorylation was decreased by metformin treatment. However, when 
stimulated by LPS, the inflammatory signaling of the WT hepatocytes / α1AMPK-/- 
macrophages co-culture was not reversed by metformin treatment, as indicated by the 
phosphorylation status of JNK1 (p46) and NF-ĸB p65 (Ser536) (Figure 13 (A)). This 
suggests that without α1AMPK in macrophages, the inflammatory status of the 
hepatocytes / macrophages co-culture cannot be suppressed, thus emphasizing the 
importance of macrophage α1AMPK in mediating the anti-inflammatory effect of 
metformin.   
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Figure 11. Treatment of CC blunts the anti-steatosis effect of metformin 
in primary mouse hepatocytes. (A) Hepatocyte fat deposition. Primary 
mouse hepatocytes were pretreated with CC for 30 min, then with metformin 
(500 µM) or PBS in the presence of palmitate (250 µM) for 24 hr and stained 
with Oil-Red-O staining. (B) Hepatocyte AMPK signaling were examined 
using Western blot analyses. Primary mouse hepatocytes were pretreated 
with CC for 30 min, then with metformin (500 µM) or PBS for 24 hr. For bar 
graph (B), data are means ± SE, n = 3 – 6. †, P < 0.05 without CC vs. CC in 
the absence of metformin (A); *, P < 0.05 and **, P < 0.01 Met vs. PBS 
(without metformin) in the presence or absence of CC.   
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Figure 12. The confirmation of α1AMPK-/- BMDM. AMPK 
expression in BMDM using Western blot analyses. 
Figure 13. Metformin treatment has no effect on decreasing inflammatory 
signaling in WT hepatocytes / α1AMPK-/- macrophages co-culture. WT 
hepatocyte / α1AMPK-/- macrophages co-culture was treated with metformin 
(500 µM) or PBS for 24 hr in the presence or absence of LPS (100 ng/ml) for 
the last 30 min. Inflammatory signaling was examined using Western blot 
analyses. For bar graphs, data are means ± SE, n = 2 – 4. *, P < 0.05 LPS + Met 
vs. LPS under the condition of WT Hep + WT BMDM. 
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DISCUSSION 
 According to the literature, it is agreeable that the mechanism of action of 
metformin is mainly AMPK-dependent, although some studies suggested that metformin 
could act through AMPK-independent pathways (173). When interpreting the data from 
the presented study, the anti-steatosis and anti-inflammatory effects of metformin seems 
to be AMPK-dependent. On one hand, the inhibition of AMPK by treatment of CC 
blunted the effect of metformin in decreasing hepatocyte fat accumulation. On the other 
hand, using a co-culture system of WT hepatocytes / α1AMPK-/- macrophages, 
metformin has limited effect in decreasing the inflammatory status of the co-culture 
upon challenged by LPS.  
 When activated, AMPK could have an anti-lipogenic effect through suppressing 
SREBP-1c activity, thus decreasing the expression of lipogenic enzymes such as ACC 
and FAS. Moreover, active AMPK could phosphorylate, thus decrease the activity of 
ACC, one of the key enzymes of de novo lipogenesis. When inhibited, AMPK should 
decrease the phosphorylation of downstream, one of which is ACC. When 
phosphorylated, ACC activity decreases, leading to a  decrease in lipogenesis (174). In 
the presented study, the treatment of AMPK inhibitor, CC, which is a cell permeable 
AMPK competitive reversible inhibitor widely used to study effects of AMPK signaling, 
resulted in an increase in fat deposition in the hepatocytes although under the presence 
of metformin. Interestingly, treatment of CC together with the presence of metformin 
resulted in even more increase in AMPK phosphorylation than that in no CC treatment. 
This paradoxical increase in AMPK phosphorylation remains to be further examined, but 
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might be due to the pretreatment of CC before treatment of metformin. Also, it is 
possible that the decrease in ACC phosphorylation in relative to phosphorylated AMPK 
upon CC treatment resulted in a decrease in fatty acid oxidation and ATP generation. 
The latter, as a feedback mechanism, causes an increase in AMPK phosphorylation.  
Consistent with this mechanism, pretreatment of CC blunted the anti-steatosis effect of 
metformin in the hepatocytes (Figure 11 (A)), indicating that CC possibly induces fat 
accumulation while bringing about an increase in AMPK phosphorylation. Considering 
the controversies regarding the selectivity of the inhibitory action of CC (175,176), it is 
also possible that CC acts through an AMPK-independent mechanism to blunt the anti-
steatotic effect of metformin.  
 Other than altering lipid metabolism, AMPK has also been widely implicated in 
regulating inflammation, specifically through mediating the NF-ĸB pathway (171). A 
recent study highlighted the importance of AMPK in regulating the inflammatory status 
of macrophages by showing that myeloid deletion of α1AMPK in mice demonstrated 
enhanced macrophage pro-inflammation (177). Knowing that macrophage/Kupffer cells 
are important in regulating inflammation during NASH (178), the presented study 
demonstrated the importance of macrophage AMPK in mediating the inflammatory 
status of the environment, as well as the anti-inflammatory property of metformin, by 
co-culturing WT hepatocytes and α1AMPK-/- macrophages treated with metformin. In 
the control (WT hepatocytes / WT macrophages co-culture), metformin was able to 
decrease the NF-ĸB signaling under LPS stimulation. However, without α1AMPK in 
macrophages, metformin was unable to decrease the phosphorylation of NF-ĸB p65 
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when challenged with LPS, likely that the pro-inflammatory status of the co-culture was 
not altered. Notably, the signaling of JNK 1 p46 also demonstrated a similar pattern in 
the metformin-treated WT hepatocytes and α1AMPK-/- macrophages co-culture under 
the stimulation of LPS. This is interesting because AMPK has also been shown to 
downregulate metabolic stress related-JNK activation through enhancing PGC-1α 
associated mitochondria biogenesis (179,180). Together, these results provided evidence 
that AMPK in macrophage is important in regulating inflammation in the liver, and that 
AMPK is partly required for the anti-steatosis effect of metformin, whereas macrophage 
AMPK is important in the anti-inflammatory property of metformin.  
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CHAPTER VII 
SUMMARY AND CONCLUSION 
SUMMARY  
 In the presented study, C57BL/6J wild-type mice were fed a high-fat diet to 
mimic obesity-induced insulin resistance and hepatic steatosis as an animal model to 
study the beneficial effects of metformin in NAFLD in vivo. As expected, metformin 
treatment not only ameliorated  insulin resistance as evidenced by an improvement in 
glucose tolerance test and insulin tolerance test, but also resulted in reduced hepatic 
steatosis as shown by liver Oil-Red-O staining, and is associated with a decrease in 
lipogenic event shown by an increase in phosphorylation of ACC and a decrease in 
mRNA expression of lipogenic enzymes such as ACC and FAS. In addition, metformin 
treatment also reduced liver inflammation as shown by a decrease in the phosphorylation 
states of NF-ĸB p65 and JNK1 (p46), and a decrease in mRNA expression of pro-
inflammatory cytokines such as TNF-α, IL-6, and IL-1β. These anti-steatosis and anti-
inflammatory effects of metformin were associated with increased liver AMPK 
activation as shown by an increase in AMPK phosphorylation. 
Interestingly the hypothesis that metformin could improve adipose tissue 
phenotype to indirectly reduce liver steatosis and inflammation was not supported by our 
data as evidenced by limited changes in adiposity and adipose tissue inflammation after 
metformin treatment. Given this, the anti-NAFLD effects of metformin appear to be 
independent of improving obesity-associated adipose tissue phenotype.   
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Further in vitro investigations showed that metformin has a direct effect in (1) 
reducing steatosis in hepatocytes, (2) reducing inflammation in both hepatocytes and 
macrophages. These are confirmed by showing a reduction in fat accumulation in 
hepatocytes, shown by Oil-Red-O staining, a reduction in mRNA expressions of 
lipogenic enzymes such as ACC and FAS after metformin treatment. Moreover, a 
decrease in phosphorylation of NF-ĸB p65 and JNK1 (p46), and a decrease in mRNA 
expression of pro-inflammatory cytokine IL-6 in hepatocytes suggested the anti-
inflammatory effect of metformin directly in hepatocyte. This anti-inflammatory effect 
of metformin was associated with an increase in AMPK phosphorylation. In addition, 
bone-marrow derived macrophages (BMDM) provided evidence for the direct effect of 
metformin in decreasing inflammation in macrophages as shown by a decrease in 
phosphorylation of NF-κB p65 and JNK1 (p46), and a decrease in mRNA expression of 
pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β.  
The present study further investigated the mechanistic insight of whether AMPK 
is necessary for the anti-steatosis and anti-inflammatory effects of metformin in the 
context of NAFLD (i.e. hepatic steatosis and liver inflammation). By using compound C 
(CC), an AMPK inhibitor, it was shown that the pretreatment of CC was able to 
attenuate the anti-steatosis effect of metformin on primary mouse hepatocytes. However, 
the pretreatment of CC together with metformin treatment resulted in a paradoxical 
increase in AMPK phosphorylation than non-CC treated hepatocytes. In addition, the 
involvement of AMPK in macrophages regulating the anti-inflammatory effects of 
metformin was further strengthened by the observation that metformin could not 
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decrease the inflammatory status in co-culture of WT hepatocytes / α1AMPK-/- 
macrophages challenged with LPS. As metformin was able to decrease the inflammatory 
status of the WT hepatocytes / WT macrophages co-culture shown by decrease in 
phosphorylation of NF-ĸB p65 and JNK1 (p46) when challenged by LPS, metformin 
treatment could not produce this effect in WT hepatocytes / α1AMPK-/- macrophages co-
culture as shown by limited changes in the phosphorylation levels of NF-ĸB p65 and 
JNK1 (p46) of the metformin- and LPS-treated WT hepatocytes / α1AMPK-/- 
macrophages co-culture. These are of particular importance because limited studies have 
examined the involvement of AMPK in macrophages in regulating the anti-
inflammatory effects of metformin in the context of NAFLD. By studying the 
involvement of AMPK in macrophage to regulate liver inflammation could not only 
provide a better understanding of the underlying mechanism of how metformin works, 
but also provide a base for further drug development that targets this aspect. For 
example, clearly AMPK in macrophages provided an important drug target. This can set 
as a platform for further discovery of bioactive compounds or a synergistic blend that 
could be as effective or even more effective than metformin. For instance, resveratrol, a 
strong antioxidant found in the skin of grapes, has been shown to activate AMPK and 
improve glucose metabolism, as well as have synergistic effect with metformin (181).  
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CONCLUSIONS 
 The presented study provided evidence that metformin not only is effective in 
improving insulin resistance, but also is effective in reducing hepatic steatosis and liver 
inflammation. This was supported by the results of the in vivo model of C57BL/6J mice 
model fed with high-fat diet to induce obesity-associated insulin resistance and NAFLD, 
and treated with metformin. Also, in the presented study, metformin did not have much 
effect in altering adipose tissue phenotype to indirectly improve liver steatosis and 
inflammation. Further in vitro studies confirm the beneficial effects of metformin is 
mainly in the liver, specifically, metformin directly decreases steatosis and inflammation 
in the hepatocytes, and also directly decreases inflammation in macrophages. Lastly, the 
involvement of AMPK in the anti-steatosis and anti-inflammatory effects of metformin 
was shown by AMPK inhibition attenuated the anti-steatosis effect of metformin in 
hepatocytes, and metformin has limited effect in decreasing the inflammatory status of 
WT hepatocytes / α1AMPK-/- macrophages co-cultures. Together, these results 
suggested that metformin is beneficial in ameliorating hepatic steatosis and liver 
inflammation, and that AMPK in macrophage is important in regulating the anti-
inflammatory effects of metformin during NAFLD.  
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